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Molecular Mechanisms of Metabolic Reprogramming in Pancreatic Cancer
Abstract
Pancreatic cancer ranks as third deadliest cancer worldwide in both men and women. The lack of
diagnostic methods, chemo-resistance and invasiveness of the disease diminishes the overall survival
rate in patients. Dysregulated glucose metabolism and several molecular determinants including
oncogenic signaling pathways play pivotal roles in the development, progression and metastasis of
pancreatic cancer. The aberrant glucose metabolism is the most prevalent key factor that influences
pancreatic tumorigenesis. The cancer cells of pancreas utilize oxygen for the breakdown of glucose to
lactate, which is known as Warburg effect. This phenotype of pancreatic cancer encourages proliferation,
growth, migration and invasive phenotypes of cancer cells that worsens the disease. The upstream
regulatory molecules responsible for deviant activity of glucose transporters during aberrant glucose
metabolism was not very well defined. Thus, identification of new molecular determinants that regulate
glucose metabolic pathway would provide promising therapeutic outcomes. Our lab has established the
role of MUC13 protein in pancreatic cancer development. Another interesting molecule, Protein Kinase D1
has been reported to play essential role in hypoxic metabolism in squamous cell carcinoma, and glucose
uptake in cardiac hypertrophy. Also, it has been extensively studied in our research group, and has been
suggested by some other groups to have an essential role in pancreatic cancer. However, its role in
regulating glucose metabolism in pancreatic cancer remains elusive. In this dissertation, we investigated
that MUC13 and PKD1 proteins are involved in abrupt glucose metabolism in pancreatic cancer cells. We
have demonstrated that targeted overexpression of these oncogenes upregulates key oncogenic
signaling components involved in aberrant glucose metabolism in pancreatic cancer cells. We also
investigated a natural agent Steviol that restored glucose metabolism in pancreatic cancer cells via
repression of MUC13 and PKD1 expression. MUC13 is a transmembrane glycoprotein which has an
elevated expression in pancreatic cancer. Due to the presence of a cytoplasmic domain, it confers kinase
activity and regulates many signaling processes. Therefore, we investigated the effect of MUC13 in
metabolic reconditioning of pancreatic cancer. As a result, it was observed that presence of MUC13 in
pancreatic cancer upregulated glucose uptake and lactate secretion. This in turn led to more aggressive
behavior of the tumor, as evidenced by enhanced proliferation, migration and invasive characteristics of
the cells as compared to MUC13 null cells. Interestingly, we observed the interaction of MUC13 with
Glut-1 protein, which influences glucose uptake in cancer cells. This was confirmed through various
assays such as: immunoprecipitation, immunofluorescence, co-capping and proximity ligation assay. The
interpretation of inhibitor results envisaged the role of NFҡB pathway during the molecular interactions of
MUC13 and Glut-1. To understand the clinical importance of this mechanism, we evaluated this
interaction in tumor samples from the patients with pancreatic disease in advanced stages. Our findings
fortified the mechanistic role of MUC13 in rewiring of aberrant glucose metabolism. Altogether, we
believed that MUC13 has clinical implication as a key molecule that might be responsible for dysregulated
glucose metabolism. As discussed earlier about the paucity of associated proteins related to
dysregulated glucose metabolism, we further investigated the possible key players with kinase domain
for association and activation with other signaling molecules. Protein Kinase D1 (PKD1), a Ser/Thr kinase
has been shown to be involved in progression of pancreatic cancer. In this study, we established PKD1 as
a novel molecular target and its involvement in regulating aberrant glucose metabolism in pancreatic
cancer. We observed that PKD1 was overexpressed in pancreatic cancer tissues compared to normal
human tissues. We also found constitutive expression of PKD1 in various pancreatic cancer cells as
compared to normal pancreatic ductal epithelial cells. The overexpression of PKD1 in low PKD1
expressing pancreatic cancer cells enhanced tumorigenic characteristics. We observed that specific
knockdown of PKD1 inhibited key oncogenic signaling components in pancreatic cancer cells suggesting
its oncogenic role in pancreatic cancer. Additionally, during the PKD1 overexpression, cells displayed
increased glucose consumption and lactate production. This suggested role of PKD1 in metabolic

reprogramming in pancreatic cancer. Also, we observed that PKD1 stimulates the glucose uptake through
mTORC1, a component of mTOR signaling pathway. Additionally, the knockdown of PKD1 promoted the
chemosensitivity of cells towards gemcitabine and 2DG (2-deoxyglucose). Overall, these results indicated
a significant function of PKD1 in rewiring of glucose metabolism in pancreatic cancer. It was mandating
to target and counteract the aberrant glucose metabolism along with the proteins identified in our
previous results. In this perspective herein, we proposed steviol, a natural sweetener from plant origin to
assess its inhibitory action towards dysregulated glucose metabolism and its associated proteins
(MUC13 and PKD1). The reason behind steviol selection for this approach includes that it mimics the
glucose molecule that facilitates enhanced uptake of drug (steviol) within the cells and on the other side,
it provides glucose homeostasis to adjacent normal cells. These features made steviol as dual functional
drug by overtaking other natural drugs for promising results. The exposure of steviol inhibited the
proliferative (IC50: 10mM) and clonogenic abilities of pancreatic cancer cells. It also suppressed the cell
migration and cell invasion capabilities of pancreatic cancer cells. Further, steviol caused the selective
inhibition of intracellular glucose intake and lactate accumulation in a concentration dependent manner.
The selective inhibition of MUC13 and PKD1 (upstream key proteins of glucose metabolism) that caused
the disruption of glucose intake in cancer cells, was observed during steviol treatment. Secondly, steviol
interfered with translation-initiation machinery, causing destabilization of the cellular functionality. The
impairment of cellular translation process had promoted G1 cell cycle arrest in cells due to the lack of
G1-S transition proteins during drug exposure. Collectively, all these events engendered the cellular
integrity and directed towards activation of apoptosis. In conclusion, we evaluated the role of MUC13 and
PKD1 in aberrant glucose metabolism leading to growth and aggressive metastatic phenotypes of
pancreatic cancer. We also demonstrated efficacy of steviol to repress aberrant glucose metabolism via
suppression of MUC13 and PKD1 proteins.
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ABSTRACT
Pancreatic cancer ranks as third deadliest cancer worldwide in both men and
women. The lack of diagnostic methods, chemo-resistance and invasiveness of the
disease diminishes the overall survival rate in patients. Dysregulated glucose metabolism
and several molecular determinants including oncogenic signaling pathways play pivotal
roles in the development, progression and metastasis of pancreatic cancer. The aberrant
glucose metabolism is the most prevalent key factor that influences pancreatic
tumorigenesis. The cancer cells of pancreas utilize oxygen for the breakdown of glucose
to lactate, which is known as Warburg effect. This phenotype of pancreatic cancer
encourages proliferation, growth, migration and invasive phenotypes of cancer cells that
worsens the disease. The upstream regulatory molecules responsible for deviant activity
of glucose transporters during aberrant glucose metabolism was not very well defined.
Thus, identification of new molecular determinants that regulate glucose metabolic
pathway would provide promising therapeutic outcomes. Our lab has established the role
of MUC13 protein in pancreatic cancer development. Another interesting molecule,
Protein Kinase D1 has been reported to play essential role in hypoxic metabolism in
squamous cell carcinoma, and glucose uptake in cardiac hypertrophy. Also, it has been
extensively studied in our research group, and has been suggested by some other groups
to have an essential role in pancreatic cancer. However, its role in regulating glucose
metabolism in pancreatic cancer remains elusive. In this dissertation, we investigated that
MUC13 and PKD1 proteins are involved in abrupt glucose metabolism in pancreatic
cancer cells. We have demonstrated that targeted overexpression of these oncogenes
upregulates key oncogenic signaling components involved in aberrant glucose
metabolism in pancreatic cancer cells. We also investigated a natural agent Steviol that
restored glucose metabolism in pancreatic cancer cells via repression of MUC13 and
PKD1 expression.
MUC13 is a transmembrane glycoprotein which has an elevated expression in
pancreatic cancer. Due to the presence of a cytoplasmic domain, it confers kinase activity
and regulates many signaling processes. Therefore, we investigated the effect of MUC13
in metabolic reconditioning of pancreatic cancer. As a result, it was observed that
presence of MUC13 in pancreatic cancer upregulated glucose uptake and lactate
secretion. This in turn led to more aggressive behavior of the tumor, as evidenced by
enhanced proliferation, migration and invasive characteristics of the cells as compared to
MUC13 null cells. Interestingly, we observed the interaction of MUC13 with Glut-1
protein, which influences glucose uptake in cancer cells. This was confirmed through
various assays such as: immunoprecipitation, immunofluorescence, co-capping and
proximity ligation assay. The interpretation of inhibitor results envisaged the role of
NFҡB pathway during the molecular interactions of MUC13 and Glut-1. To understand
the clinical importance of this mechanism, we evaluated this interaction in tumor samples
from the patients with pancreatic disease in advanced stages. Our findings fortified the
mechanistic role of MUC13 in rewiring of aberrant glucose metabolism. Altogether, we
believed that MUC13 has clinical implication as a key molecule that might be responsible
for dysregulated glucose metabolism.
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As discussed earlier about the paucity of associated proteins related to
dysregulated glucose metabolism, we further investigated the possible key players with
kinase domain for association and activation with other signaling molecules.
Protein Kinase D1 (PKD1), a Ser/Thr kinase has been shown to be involved in
progression of pancreatic cancer. In this study, we established PKD1 as a novel
molecular target and its involvement in regulating aberrant glucose metabolism in
pancreatic cancer. We observed that PKD1 was overexpressed in pancreatic cancer
tissues compared to normal human tissues. We also found constitutive expression of
PKD1 in various pancreatic cancer cells as compared to normal pancreatic ductal
epithelial cells. The overexpression of PKD1 in low PKD1 expressing pancreatic cancer
cells enhanced tumorigenic characteristics. We observed that specific knockdown of
PKD1 inhibited key oncogenic signaling components in pancreatic cancer cells
suggesting its oncogenic role in pancreatic cancer. Additionally, during the PKD1
overexpression, cells displayed increased glucose consumption and lactate production.
This suggested role of PKD1 in metabolic reprogramming in pancreatic cancer. Also, we
observed that PKD1 stimulates the glucose uptake through mTORC1, a component of
mTOR signaling pathway. Additionally, the knockdown of PKD1 promoted the
chemosensitivity of cells towards gemcitabine and 2DG (2-deoxyglucose). Overall, these
results indicated a significant function of PKD1 in rewiring of glucose metabolism in
pancreatic cancer.
It was mandating to target and counteract the aberrant glucose metabolism along
with the proteins identified in our previous results. In this perspective herein, we
proposed steviol, a natural sweetener from plant origin to assess its inhibitory action
towards dysregulated glucose metabolism and its associated proteins (MUC13 and
PKD1). The reason behind steviol selection for this approach includes that it mimics the
glucose molecule that facilitates enhanced uptake of drug (steviol) within the cells and on
the other side, it provides glucose homeostasis to adjacent normal cells. These features
made steviol as dual functional drug by overtaking other natural drugs for promising
results. The exposure of steviol inhibited the proliferative (IC50: 10mM) and clonogenic
abilities of pancreatic cancer cells. It also suppressed the cell migration and cell invasion
capabilities of pancreatic cancer cells. Further, steviol caused the selective inhibition of
intracellular glucose intake and lactate accumulation in a concentration dependent
manner. The selective inhibition of MUC13 and PKD1 (upstream key proteins of glucose
metabolism) that caused the disruption of glucose intake in cancer cells, was observed
during steviol treatment. Secondly, steviol interfered with translation-initiation
machinery, causing destabilization of the cellular functionality. The impairment of
cellular translation process had promoted G1 cell cycle arrest in cells due to the lack of
G1-S transition proteins during drug exposure. Collectively, all these events engendered
the cellular integrity and directed towards activation of apoptosis.
In conclusion, we evaluated the role of MUC13 and PKD1 in aberrant glucose
metabolism leading to growth and aggressive metastatic phenotypes of pancreatic cancer.
We also demonstrated efficacy of steviol to repress aberrant glucose metabolism via
suppression of MUC13 and PKD1 proteins.
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CHAPTER 1.

INTRODUCTION

Pancreatic Cancer
Pancreatic cancer is one of the leading causes of cancer-related deaths in the
United States, and soon is expected to become the second deadliest type of cancer [1].
Therefore, it is of utmost importance to develop effective strategies to tackle this lethal
disease. Pancreatic tumors become highly resistant to the individual chemotherapies.
Inaccessible location of the pancreas, late diagnosis, lack of knowledge of molecular
determinants, chemoresistance and altered glucose metabolism are the key factors
responsible for the aggressiveness of this deadly disease [2, 3]. In addition to this, several
oncogenic signaling pathways play pivotal role in the development, progression and
metastasis of pancreatic cancer. Hence, identification of new molecular factors, which
play pivotal role in altered glucose metabolism and chemoresistance in pancreatic cancer
are urgently required.
Statistics, Disease Prognosis and Risk Factors
The statistics for pancreatic cancer are extremely alarming. It has been estimated
that more than 55,000 people will be newly diagnosed with this disease in the US,
including both men and women. This data indicates the severity of this disease [1]. The
global sporadic spread of this cancer was profound in Western countries belonging to
North America and Europe. This disease accounts to 3% of the globally occurring
cancers with mortality rate of 7 %, a major contributor to cancer-related deaths [4]. At the
time of diagnosis, 80% of the patients have advanced metastatic pancreatic cancer [5].
The major risk factors involved in disease progression depend on familial and living
lifestyle of the patients that encloses smoking, diabetic positivity, and genetic history [6].
More often, the high rate of pancreatic cancer incidence has been reported in elder people
with age of 60 or more, but in few cases, the disease has been diagnosed in young
individuals too [7]. Other risk factors include alcohol, obesity, infection (especially with
Helicobacter pylori), diet intake and gut microbiome [8].
Pancreatic Cancer and Tumor Metabolism
Pancreatic tumors are very active metabolically owing to the activation of various
oncogenic molecules which aberrantly dysregulate metabolic activities leading to growth,
proliferation and drug resistance. The cancer cells have enhanced energy needs to sustain
and thus facilitates alterations in constitutive metabolic pathways [9]. It has been reported
that pancreatic tumors uptake more fluoro-2-deoxyglucose (FDG) as confirmed by PET
(Positron Emission Tomography) [10].
Metabolic reprogramming refers to the increased rate of crucial metabolic
processes within the cells during tumorigenic conditions. These include elevated
1

glycolysis, pentose phosphate pathway, hexosamine pathway, serine biosynthesis
pathway, and lipid and fatty acid metabolism.
Glucose Metabolism in Normal versus Cancer Cells
Altered glucose metabolism is known to facilitate cancer cell proliferation and
survival [11]. The tumor cells highly depend on glucose metabolism for their growth as
compared to normal cells. However, the cells with normal constitutive gene expression
survive through intake of glucose as energy fuel. These normal cells convert glucose into
pyruvate in order to yield energy through glycolysis process for their survival and
growth. Subsequently after glycolysis, the initiation of Kreb’s cycle promotes the
conversion of pyruvate to CO2, and followed by the oxidative phosphorylation leading to
the formation of 36 ATP molecules for each glucose molecule. Whereas, in cancer cells,
lactate accumulations are predominant that promotes cells towards high rate of
proliferation, transforming them towards invasive form, with generation of 2 ATPs [12].
This mechanism is depicted (Figure 1-1). Overall, knowledge on the signaling molecules
controlling tumor glucose metabolism is limited which provides a major roadblock for
the therapeutic targeting.
Warburg Effect
Warburg effect is a classical phenomenon discovered by Otto Warburg in 1924,
and is widely researched [13]. According to Warburg effect, the cancer cells even under
regular oxygen levels, produce abundant amount of lactate. This effect is also referred to
as aerobic glycolysis [14]. Under this condition, glucose is consumed and transported to
cancer cells, and leading to the excessive lactate accumulations [13]. The production of
accumulation of lactate encourages proliferation and growth of cancer cells, which
induces an aggressive phenotype. It is the main source of energy requirement for the
cancer cells, and thus is a remarkable feature of the tumorigenic phenotype of cells.
Alterations in Glucose Metabolic Pathways in Pancreatic Cancer
Glycolysis
Glycolysis is a biological process prevalent in the cancer cells. These cells utilize
the several regulatory pathways to achieve their metabolic requirements and also in order
to adapt to the tumor microenvironment. This pathway is composed of many reversible
steps and three irreversible steps. These steps are also referred as the committed steps.
Out of these steps, the first one involves the hexokinases which leads to the generation of
glucose-6-phosphate (G6P) from glucose. This step is very significant as glucose
molecule is facilitated to enter the cells, and also because it is the branching point for
pentose phosphate pathway (PPP), glycogenesis and hexosamine synthesis pathway [15].
2

Figure 1-1. Differences Between Normal Cell and Cancer Cell Metabolism
The cancer cells are more metabolically active compared to the normal cells due to the
enhanced glycolytic flux, ultimately resulting in increased cell proliferation and
tumorigenic features.
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Lactate is an end product of glycolysis, and was not an attractive target until few
years. But in recent years, it has evolved as a promising target for cancer metabolism. It
has been reported that increased levels of lactate are directly proportional to enhanced
cancer cell proliferation, growth, and metastasis. They transport lactate to proximal
cancer cells, stroma and other regions such as the endothelial cells, which leads to
metabolic alterations. It also promotes angiogenesis of tumors. Therefore, it is considered
as an essential target for cancer therapeutics nowadays. Lactate dehydrogenase A
(LDHA) is a critical enzyme involved in cancer cell metabolism. The other isoform is
lactate dehydrogenase B (LDHB). Precisely, LDHA is the mainly expressed isozyme in
cancer cells. Both these isozymes are capable of forming homo- or hetero-tetramers [16,
17]. Increased levels of LDHA is associated with tumor progression involving high rates
of glycolysis, and makes the prognosis of the disease extremely difficult [18]. Also, many
genetic studies have indicated that targeting this enzyme can be extremely useful for
cancer therapy.
The cancer cells export lactate, instead of utilizing them as an energy source. This
leads to acidification of the tumor microenvironment [19]. Monocarboxylate transporters
(MCT) are used to transport lactate and protons under high glycolytic conditions.
Therefore, they can control the pH and lactate concentration in cell. There are four
isoforms of MCT transporters- MCT1, MCT2, MCT3 and MCT4 [20]. Of these, high
levels of MCT1 and MCT4 indicate tumorigenic condition and poor prognosis in
different types of cancer [21-26]. But their role in pancreatic cancer is still unknown.
It has been reported that the transcription factor Forkhead box protein M1
(FOXM1) enhances aerobic glycolysis (Warburg effect), and induces lactate
dehydrogenase A (LDHA) expression, thereby leading to progression of pancreatic
cancer. Therefore, targeting the FOXM1-LDHA signaling pathway can be useful for
pancreatic cancer treatment [27].
Pentose Phosphate
Pentose phosphate pathway branches out from glycolysis and plays an essential
role in fulfilling the anabolic requirements of cancer cells, and also to inhibit the
oxidative stress of the cells. This pathway has both oxidative, as well as non-oxidative
mechanisms. The oxidative arm mainly leads to production of NADPH and ribulose-5phosphate, mainly in three different irreversible steps. The non-oxidative arm of this
pathway produces pentose phosphates, such as ribose 5-phosphate, which is essential for
synthesis of nucleic acids and further leading to increased cell proliferation. Some other
molecules are also involved in these processes such as fructose-6-phosphate and
glyceraldehyde-3-phosphate[28, 29]. This overall pathway is illustrated in Figure 1-2.
As this pathway generates NADPH, which is utilized for the production of fatty
acids and also for pentose phosphate molecules, it has a significant role in tumor cell
metabolism. The level of cellular metabolism and redox potential determines the
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Figure 1-2. Pentose Phosphate Pathway
The enzymes hexokinase 1 (HK1) and hexokinase 2 (HK2) generate glucose 6-phosphate
from glucose by utilizing the ATP molecule produced during oxidative phosphorylation
(OXPHOS).
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oxidative and non-oxidative mechanisms. This pathway is regulated by many agents, and
in cancer cells both mechanisms (oxidative and non-oxidative) of this pathway are
accelerated by various oncogenes [28, 29]. The tumor cells mainly utilize the nonoxidative branch of this pathway to produce nucleotides for RNA/DNA generation. This
has been reported in some study that about 80% of the nucleotides are obtained through
the nonoxidative arm of this pathway [30].
The most important role of the PPP in the context of carcinogenesis is its
protective role from cell death. Recently, it has been identified that the emerging lesions
of cancer cells can regulate the fluctuations of this pathway. The enzymes which are
involved in this pathway are very critical in regulating the rate and the functioning of this
pathway. This is led by various mechanisms which determine the regulation and activities
of these enzymes. The activation of glucose-6-phosphate dehydrogenase (G6PDH) is
mediated by activation of various pathways such as PI3K/Akt and Ras. The increased rate
of PPP in proliferating cells is one of the distinguishing factor from quiescent cells. It has
been reported that the occurrence of drug resistance occurs due to the increased levels of
PPP in various cancers. Also, oxidative stress [31], radiations [32] and some other
chemotherapeutic agents [33] contribute towards the elevated levels of this pathway,
which further results in increased ROS generation.
The increased levels of G6PDH are indicators of high oxidative mechanism in this
pathway, after the occurrence of drug resistance. But this resistance can be overcome by
some agents such as DHEA or 6-AN, as reported in colon cancer. These molecules are
capable of restraining the first two steps of the oxidative branch of the PPP [34]. During
dysregulated condition of this pathway, increased growth and proliferation of cancer
occurs. Proper understanding of this pathway and its correlation with glycolysis can
enable the emergence of effective therapeutic targeting.
Hexosamine Pathway
Hexosamine pathway branches from glucose metabolism and is initiated by
glucose-6 phosphate and fructose-6 phosphate. It has been reported that this pathway has
a significant role in tumor progression and insulin resistance [35, 36]. About 5% of
glucose is utilized in this pathway which is then converted to fructose-6-phosphate (F6P)
in two steps. Further, the enzyme glutamine:fructose-6-phosphate amidotransferase
(GFAT1) catalyzes the rate-limiting step of this pathway. The amide group on glutamine
gets transferred to F6P leading to the formation of GlcN-6-P, and this reaction is
catalyzed by GFAT1. The pancreatic cancer cell lines are very responsive to glutamine
starved conditions. Therefore, GFAT1 enzyme is able to combine the glucose as well as
glutamine metabolism, and leads to tumor progression. In a study, it was found that
elevated level of this enzyme results in poor prognosis of patients suffering from
pancreatic cancer [37]. In another study, it was reported that the genetic variations of this
enzyme can lead to risks of pancreatic cancer development [38]. The end product of
hexosamine pathway, UDP-N-acetylglucosamine (UDP-GlcNAc) is involved in the post-
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translational modification of several proteins through O-linked β-Nacetylglucosamine (OGlcNAc). This Hyper-O-GlcNAcylation mechanism is anti-apoptotic and results in
activation of NFκB pathway in PDAC [39]. In another study, the researchers found that
by altering the Sp1 (transcription factor regulating cancer cell survival and proliferation)
modification mechanism through O-GlcNAc, pancreatic cancer cell death occurs through
triptolide, which is undergoing phase I clinical trials [40]. Glycogen is produced during
this process, and can act as an alternative for glucose when it is limited for cancer cells
[41]. This mechanism is shown in illustration (Figure 1-3).
Serine Biosynthesis
The serine biosynthesis pathway (Figure 1-4) involves the production of 3phospohoglycerate (3PG) during glycolysis to form some non-essential amino acids. The
enzyme phosphoglycerate dehydrogenase (PHGDH) is inhibited in certain cancer cells.
The initial step in this pathway is catalyzed by PHGDH, leading to the formation of 3phosphohydroxypyruvate. Inhibitors of this enzyme have recently been reported, and it
was found that they inhibited the growth and proliferation of cancer cells which had
increased rate of serine biosynthesis. Few of these inhibitors are currently undergoing
clinical studies and some are approved for therapies as well [15]. PHGDH is required for
the proliferation of cancer cells with or without the availability of serine. Therefore, it is
unclear what leads the cancer cells to increase the activity of the initial steps of this
pathway. Excessive amount of serine accounts for increased glycolysis rate leading to
tumorigenesis [42].
Liver kinase B1 (LKB1) is a known tumor suppressor. In a recent study, it was
observed that loss of LKB1 is linked to serine metabolism in pancreatic cancer, and leads
to DNA methylation and tumor progression. The researchers found that due to activation
of the serine-glycine-one-carbon pathway, in conjunction with S-adenosylmethionine
formation, through mTOR, there was increased correlation between loss of LKB1 and
activation of KRAS [43]. In another study, the researchers investigated if the uptake of
fluorine-18 fluorodeoxyglucose (FDG) has any association with mTOR signaling
pathway. They observed that the expression levels of Glut-1, p70S6 and EGFR were
correlated with FDG uptake, and this in turn was associated with glucose metabolism and
tumorigenesis in pancreatic cancer patients [44].
Fatty Acids and Lipid Metabolic Signaling
Fatty acids serve as an energy source for tumor cells, and act as precursors for
catabolism in cancers. Their metabolism is modulated by 5’-AMP-activated protein
kinase (AMPK), which gets activated when less ATP is produced. Increased levels of
fatty acids are one of the important factors for aberrations in the metabolic pathways of
cancer cells. It leads to increased cancer cell proliferation and survival, and the
knockdown of essential enzymes associated with fatty aid metabolism enables the
retardation of cell growth and survival [45].
7

Figure 1-3. Hexosamine Pathway
This is an intermediate pathway which is essential for the production of glycosylation
molecules.

8

Figure 1-4. Serine Biosynthesis Pathway
This pathway uses the 3-phosphoglycerate produced during glycolysis to generate 3phosphohydroxypyruvate. In the following step, 3-phosphoserine is produced, which is
later converted to serine. This molecule (serine) is consumed during folate metabolism
and methionine cycle.
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In a recent research, it was found that the serum fatty acid synthase (FASN) had
high levels and it was considered as an indicator of neoplasia. Based on the data, it
showed a potential for a therapeutic target. In some other research, it was found that some
PDAC cells are able to get fatty acids through circulation, liver, adipose tissues for their
proliferation [45]. These correlations can be exploited in the future for evaluation of new
therapeutic targeting strategies for pancreatic cancer.
The cancer cells require fatty acids for their proliferation. In another study, it was
found that by inhibiting fatty acid synthesis, the pancreatic cancer cells undergo more
apoptosis. In this study, an inhibitor of lipid synthesis: 5-(tetradecyloxy)-2-furoic acid
(TOFA) was used. It inhibited AC carboxylase (ACC). Further, they also assessed the
efficacy (in inhibiting the proliferative abilities of pancreatic cancer cells) of fatty acid
synthase inhibitors: cerulenin and irgasan. It was observed that these inhibitors markedly
decreased the proliferation of the pancreatic cancer cells [46]. Some researchers have also
studied the role of fatty acids and metabolic pathways (mevalonate) towards the growth
and proliferation of pancreatic cancer stem cells [47]. The fatty acid/lipid metabolism
process is illustrated through Figure 1-5.
Glutamine Metabolism
Glutamine is an amino acid which is highly used by the cancer cells to fuel
anabolic metabolism processes. This nutrient is used mainly for cellular growth, and
through the Kreb’s cycle, it can be metabolized to generate energy. It also contributes to
synthesis of fatty acids in cells under hypoxic conditions. In case of lipid synthesis, it
serves as a carbon donor instead of glucose. Also, it is critical for glutathione production,
which is essential for growth and proliferation of tumor cells during oxidative stress and
depicted in Figure 1-6. In PDAC, a different role of glutamine is to transaminate
glutamate and oxaloacetate into α-ketoglutarate and aspartate. In a study, the authors
have identified that oncogenic KRAS plays an important role in altering glutamine
metabolism. Therefore, targeting this pathway can provide effective therapeutic strategies
for PDAC patients [48]. Researchers have found that by transfer of glutamine, adipocytes
increase cell proliferation in pancreatic cancer [49]. Research has shown that glutamine
anaplerosis decreases growth and proliferation of pancreatic cancer by inhibition of
autophagy [50]. In normal cells, glutamate dehydrogenase (GLUD1) is used in the
mitochondria for the conversion of glutamate into α-ketoglutarate during the TCA cycle.
But in PDAC, aspartate gets converted into oxaloacetate through aspartate transaminase
(GOT1), which takes place in the cytoplasm. Further, the oxaloacetate gets converted to
malate and later to pyruvate. This increases the NADPH/NADP (+) ratio and leads to the
maintenance of redox state in the cells. The researchers established that oncogenic KRAS
is strongly involved in the metabolic reprogramming of glutamine, and therefore
targeting this pathway can provide novel therapeutic strategies for the treatment of these
deadly tumors [48].
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Figure 1-5. Fatty Acid and Lipid Metabolism
Elevated levels of fatty acids and lipids, both account for metabolic aberrations in cancer.
This further leads to increased cell proliferation and metastatic characteristics in cancer
cells.

Figure 1-6. Glutamine Metabolic Pathway
This pathway is also utilized by cancer cells for their rapid growth and to obtain energy.
GLS1 and GLS2 refers to glutamine synthase 1 and glutamine synthase-2 enzymes
respectively.
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One-Carbon Metabolism Cycle
Serine and glycine are responsible for one-carbon metabolism to form
nucleotides. This cycle generates precursor molecules such as NADPH for other
pathways such as methionine and purine synthesis cycle, and is also involved in
methylation. For this, transfer of carbon groups takes place and the reactions are
facilitated by various enzymes and intermediates. Many inhibitors for the enzymes for
this pathway have been identified and are currently under clinical trials [51].
Oncogenic Signaling Implicated in Pancreatic Tumorigenesis
KRAS Signaling
KRAS signaling pathway is the most prevalent pathway involved in pancreatic
cancer. About 95% of pancreatic tumors harbor KRAS mutation [52]. It is well studied
that oncogenic form of KRAS is involved in metabolic alterations of cancer cells [53].
KRAS mutations also serve as an important factor in the growth, progression and
resistance mechanisms of pancreatic cancer [54]. This molecular signaling mechanism
also upregulates proliferation of cells, migratory potential and autophagy in cells [55]. A
schematic depicting KRAS signaling with respect to glucose metabolism is illustrated in
Figure 1-7.
c-Myc Signaling
c-Myc is an oncogenic molecule which regulates cell growth and metabolism.
Due to its involvement in various associated processes, it is considered as a “master
regulator” [56]. It is also a crucial transcriptional factor associated with cancer. [57].
Studies have suggested that c-Myc is associated with glycolysis [58]. It is also involved
in Warburg effect, as it increases the expression level of associated genes in this process
[59]. Various studies have indicated that c-Myc is associated with pancreatic
carcinogenesis, and therefore its suppression can have beneficial therapeutic outcomes
for PDAC [60]. It performs a plethora of functions as depicted in Figure 1-8.
Glut-1
Glut-1 stands for Glucose transporter-1 and belongs to the GLUT family. It
facilitates the uptake of glucose within the cells. A schematic depicting the role of Glut-1
is shown in Figure 1-9. Glut-1 is present in endothelial cells, red blood cells, blood-brain
barrier regions as well as in placenta [61, 62]. Its overexpression leads to high glucose
metabolism [63]. Many reports have suggested that overexpression of Glut-1 directly
correlates with increased tumorigenic features, and thus it can be used as a biomarker for
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Figure 1-7. Mechanism of KRAS Signaling
This molecular pathway is predominant in pancreatic cancer, and is also closely
associated with aberrant glucose metabolism.

Figure 1-8. c-Myc Regulation
This oncoprotein is involved in various cellular functions as depicted in this figure.
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Figure 1-9. Schematic Representation of Function of Glut-1 in Cells
Glucose is taken inside the cells when glucose molecule binds to the Glut-1 receptor on
the cell membrane and is later released within the cell. The glucose molecule is further
used by the cells to generate energy in the form of ATP. (Original individual figure
components were made using Motifolio software).
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pancreatic cancer. The other glucose transporters are GLUT2, GLUT3 and GLUT4, but
GLUT1 is the prominent one [61].
Of all the glucose transporters, Glut-1 is believed to be involved in the
consumption of FDG (fluorodeoxyglucose), which is a method to detect hypoxic
condition within the tumors, through PET (positron emission tomography) technique
[64]. Compelling evidences indicate Glut-1 can be a prognostic marker as well as a
therapeutic molecule to target pancreatic carcinogenesis [65, 66].
HIF-1 α
HIF-1 α stands for Hypoxia-inducible factor α. It is an important transcription
factor which helps tumor cells to survive under hypoxia. It enhances tumorigenic
condition by increasing the expression of genes associated with metabolism. It is a key
molecule which regulates cancer metabolism through stimulation of essential genes
involved in glycolytic pathway.
Hypoxia inducible factors are formed of two parts: α- subunit, and a β-subunit.
The alpha (α) portion is sensitive to oxygen. HIF-1 α is a key molecule which controls
the oxygen homeostasis in cells, and in turn functions in various pathophysiological
conditions, growth and development [67, 68]. Under hypoxic conditions, the genome
becomes very unstable and repair of DNA gets ineffective. This in turn leads to a
tumorigenic condition [69]. The various functions of HIF-1 α are illustrated in Figure
1-10.
NFκB
NFκB is a principal regulator involved in various pathological conditions such as:
cancer, autoimmune diseases and inflammation. It plays a key function in the metabolic
adaptation of both normal and tumor cells, and also controls mitochondrial respiration
[54].
The NFκB complex includes the p65 protein, the p50 protein and the inhibitory IκB
kinase (IKK) protein. In inactive state, NFκB protein is present in the cytoplasm, but in
the activated state it translocates to the nucleus [70]. NFκB protein is associated with
tumor growth and subsequent progression. Therefore, several studies have been
conducted to exploit this pathway as a potential therapeutic strategy to target various
cancers, including pancreatic cancer.
mTOR
The mammalian target of rapamycin (mTOR) is a prime player of the PI3K
signaling. It is involved in several aspects such as: cellular growth and proliferation with
respect to the energy level and nutrient source [71].
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Figure 1-10. Various Functions of Hypoxia
(A) Schematic showing the changes in morphology of normal and cancer cells during
hypoxia. (B) The involvement of hypoxia in various cellular functions is mentioned.
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mTOR complex subsist in two different isoforms viz., mTORC1 and mTORC2. The
phosphorylation site for mTORC1 is S2448, whereas for mTORC2, it is S2481. Also,
mTORC1 is sensitive to rapamycin, but mTORC2 is not. The two complexes are
different in the type of proteins they are associated with [72]. The mTORC1 is comprised
of mTOR, mLST8 and raptor proteins while mTORC2 complex is composed of mTOR,
PRR5, mSIN1, mLST8 and rictor proteins [73].
The major proteins involved in mTORC1 pathway are 4EBP1 and S6kinase. On
the other hand, AKT is the main player in mTORC2 pathway. Inefficient functioning of
this pathway leads to various pathological conditions such as: diabetes, cancer, and heart
diseases [73].
Apoptosis
This is one of the most common mechanisms involved in multicellular organisms.
It is also known as programmed cell death. This mechanism is important for cellular
homeostasis and proper development of the organisms [74]. Apoptosis is subdivided into
extrinsic, and intrinsic pathways [75]. These two pathways (both intrinsic and extrinsic)
have distinct functions in promoting cell death, that enables conventional functioning of
the cellular processes.
During the extrinsic process, many proteins are involved that activate apoptosis.
These proteins are specifically associated with the death receptors, such as Fas, the tumor
necrosis factor (TNF) and TRAIL (TNF-related apoptosis-inducing ligand) [76, 77]. This
process activates another protein, Fas-associated death domain (FADD), leading to the
creation of DISC (death-inducing signaling complex). This is followed by stimulation of
procaspase8 and other caspases, finally resulting in apoptosis of the cells [74].
The intrinsic pathway occurs in the mitochondria, where it begins with the
lysosome breakdown followed by several steps. Upon activation, the proteins associated
with the Bcl-2 family produces cytochrome c after mitochondrial translocation.
Thereafter, caspase-3 is activated, and apoptosis occurs through key associated proteins
[78].
Translation Initiation
The translation initiation process in eukaryotes is very complex. This
phenomenon involves many factors and proteins, each operating different functions.
Mainly, there are 6 eukaryotic initiation factors (eIFs): eIF1, eIF2, eIF3, eIF4, eIF5 and
eIF6 [79]. It has been suggested that inappropriate regulation of the translation machinery
results in tumor initiation and progression. Therefore, the molecules associated with this
machinery are considered as emerging targets for therapeutic intervention of cancer [79].
The main proteins involved with the translation initiation complex are: eIF4B, eIF4E and
eIF4G. They form a complex and tightly regulate the translation process.
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In the normal cells, this process is involved in the expression of genes, energy
sources, and formation of ribosome. Whereas, in the tumorigenic status, the translation
initiation pathway translates to a highly oncogenic form [80, 81].
Functional Role of MUC13
MUC13, a mucin member of glycoprotein family with molecular weight of 50150 kDa with induced expression pattern in pancreatic cancer. It has minimal expression
in normal cells and has been reported to play a significant role in cancer progression, as
well as modulating several tumorigenic signaling pathways [82].
In our previous publication, MUC13 has been reported to interact with Her2
protein, which promotes the progression of PDAC [83]. This protein also has enormous
clinical importance as a diagnostic biomarker for pancreatic cancer, as elucidated in our
recent publication [84]. However, the role of MUC13 in driving aberrant glucose
metabolism in pancreatic cancer has never been investigated.
Structure of MUC13
The MUC13 structure is mainly composed of two domains: α-domain and βdomain. The α-domain consists of the TR (Tandem Repeat) domain, and the EGF-like 1
domain. In addition, the β-domain has the EGF-like 2 and 3 regions, TM (transmembrane
domain), and the cytoplasmic-tail domain (containing the phosphorylation sites). The
intermediate domain (SEA) is the cleavage region for proteins, and also contains a motif
region for interaction between proteins.[82]. These domains of MUC13 protein are
responsible for the oncogenic profile.
The large domain with glycosylation sites outside the cells primarily contributes
for attachment of the cells with outside matrix. On the other hand, the cytoplasmic
domain of MUC13 is involved in the cell signaling mechanisms, as it contains the
phosphorylation sites. This protein is suggested to have potential as a biomarker to detect
cancer [85]. The structure of MUC13 is shown in Figure 1-11.
Functional Aspects of PKD1
PKD1 is a kinase protein which plays important roles in many signaling
pathways. It is involved in cell proliferation, cell survival, cell-cell adhesion, cell
migration, etc. There are three family members of the Protein Kinase D family:
PKD1/2/3 [86]. Among the three isoforms, PKD1 is the most prevalent member of the
family with an extensive functional role in progression of pancreatic cancer. It is mainly
present in the cytoplasm of cells, and in sparse amount in the Golgi body and also in the
mitochondria [86].
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Figure 1-11. Structure of MUC13 Protein
Representative figure depicting the structural components of MUC13. The different
domains of this protein are involved in various functions. SEA domain contains the
cleavage site, and lies between the α-subunit and the β-subunit of the MUC13 protein.
The cytoplasmic domain comprises of a Protein Kinase C (PKC) motif, which suggests
its role in various cell signaling processes. TR and TM domain refers to tandem repeat
and transmembrane domains respectively. (Idea of this figure was taken from Maher et
al., 2011 [85]).
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Previous reports have indicated that PKD1 can be a marker for tumor detection in
the initial stages, and also be a promising drug target for pancreatic cancer [87] Another
study suggested that stimulation of PKD1 through oxidative stress can lead to pancreatic
tumor invasive phenotype [88] Other researchers had previously reported that PKD1
enhances growth, angiogenesis, and invasive features of pancreatic cancer, and thus can
be exploited for therapeutic purposes [89]. Despite of having a potential role in pancreatic
cancer pathogenesis, the underlying signaling mechanisms regulated by PKD1 has not
been completely elucidated. So far, no studies have been investigated about the clinical
implications of PKD1 in glucose metabolism of pancreatic cancer.
Structure of PKD1
PKD1 protein is composed of 912 amino acids with molecular weight of 115 kDa.
The structure of PKD1 is divided into two distinct domains: the regulatory domain and
the catalytic domain flanked through the N-terminal to the C-terminal regions [86].
The regulatory region is composed of alanine-proline (AP) rich domain, cysteinerich domain, amino-acid domain and a pleckstrin homology (PH) domain [86]. Each of
these regions possess distinct functions. The exact function of the AP region has not been
elucidated yet. However, its suggested possible role can be in lipid binding [90], and
providing proper protein conformation as well as maintenance of PKD1 stability [91].
The cysteine-rich regions are essential for binding of lipids, and the PH region is
involved in interaction of protein with proteins/lipids [92]. The structure of PKD1 is
shown in Figure 1-12.
In this dissertation, we demonstrate the role of MUC13 and PKD1 involved in
regulating glucose metabolism, further leading to growth and aggressive metastatic
phenotypes of pancreatic cancer (Chapter 2 and 3).
Current Treatment Options for Pancreatic Cancer
Very limited number of treatment options are available for pancreatic cancer. If
detected early, surgery is also an option. But in the metastatic state, a combination of
drugs named, FOLFIRINOX is employed. This chemotherapy option contains the drugs:
oxiplatin, leucovorin, fluorouracil and irinotecan [93]. The available therapeutic options
for pancreatic cancer are: chemotherapy, radiotherapy, resectable surgery and
combination of chemotherapy and radiotherapy [94] Most of the times, the standard
regimen employed is the drug gemcitabine along with 5-FU (5-fluorouracil) [95].
Gemcitabine is preferred over other drugs as it has minimal toxicity and high tolerance
capabilities [96]. On the other hand, 5-FU is mainly used when a patient is unable to
respond to gemcitabine [97].
It has been observed that all patients do not have uniform response towards
FOLFIRINOX. Therefore, other combinatorial options have been approved by FDA such
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Figure 1-12. Structure of Protein Kinase D1
Schematic diagram representing the different functional domains of PKD1 protein. The
various domains of PKD1 protein are mentioned in the inset. The
activation/phosphorylation of the kinase domain occurs at S744 and S748 sites. This in
turn leads to release of inhibition by itself and also at S916 site, autophosphorylation
occurs. (The idea of this schematic diagram emerged from Sundram et al., 2011 [86]).
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as paclitaxel (albumin-bound) along with gemcitabine, and they have demonstrated better
efficiency [98]. Accumulating evidences suggest that aberrant glucose metabolism plays
pivotal role in the development, progression and metastasis of pancreatic cancer. Several
glucose metabolic targeting agents have been discovered which show potent therapeutic
efficacy against pancreatic cancer and are discussed below.
Molecular Targeting of Glucose Metabolism in Pancreatic Tumors
Therapies targeting tumor metabolism can inhibit growth of tumors. The tumor
metabolism can be inhibited by reduction of glucose uptake and its further secretion into
lactate. It can also be targeted by inhibition of signaling pathways involved in cancer
growth and less availability of essential nutrients required for growth and proliferation.
Previous research had suggested that 2-deoxyglucose (2-DG) treatment, which is
a known suppressor of glycolysis, results in reduction in pancreatic cancer cell viability
mediated by oxidative stress mechanism and also by abnormalities in thiol metabolic
pathway [99]. Recent studies by Chapiro et al. [100], demonstrated the therapeutic
efficacy of microencapsulated 3-bromopyruvate (3-BrPA), which was assessed in
orthotopic xenograft mouse models of PDAC. It represented the systemic delivery of the
formulation as an antiglycolytic tumor treatment. The results showed remarkable
anticancer effects with no toxicity, which warrants clinical trials in PDAC patients [101].
One of the mTOR inhibitors, everolimus is also a metabolism inhibitor, and has shown
promising results in pancreatic tumors, as well as several other types of tumors [102].
EZN-2968 is an antisense oligodeoxynucleotide and an inhibitor of HIF-1 α, which has
demonstrated distinct results in phase I clinical trials [103].
Previous studies have suggested that the various sources of energy are responsible
for the different metabolic phenotypes in PDAC. Therefore, targeting these phenotypes
with their individual inhibitors can provide an effective therapeutic strategy for PDAC
patients [104]. The derivative of perylene (TEL03) is known to regulate HIF-1α and
STAT3 signaling. This derivative is a dual inhibitor, which can target both these
pathways, in pancreatic cancer [105]. Previous research had shown that the histone
deacetylase (HDAC) inhibitor, chidamide is a potent anti-cancer agent. The researchers
have identified that its mechanism of action is by inhibiting the aerobic metabolism and
degradation of Mcl-1, and leading to reduced cell proliferation of pancreatic cancer cells
[106]. Recent studies have identified the anti-cancer role of this inhibitor in pancreatic
cancer cells [107]. Chidamide is being tested in clinical trials in China and the US for its
therapeutic efficacy in pancreatic cancer [108]. A TGF-beta receptor I kinase inhibitor,
galunisertib, has shown promising results in phase I clinical trials in pancreatic cancer
patients [109].
The glycolysis of tumor cells can be exploited as attractive molecular target in
chemotherapy. [110]. Some researchers have highlighted the importance of mitochondrial
glutaminase 1(GLS1) inhibitors and β-lapachone for high selectivity in PDAC patients
[111]. New researches involve the combined use of modulation of the autophagy
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mechanism (through autophagy inhibitors) with anticancer therapy regimens [112].
Another inhibitor which is undergoing investigation is metformin. It is an inhibitor of the
electron transport chain [113]. Other research groups have suggested the importance of
metformin and some β-blockers for controlling the emergence of pancreatic cancer [114].
In a recent research, an inhibitor of glutamine was used and through nanoparticle-based
drug delivery approach, in combination with metformin, reduced pancreatic tumor
growth [115].
Hexokinase II (HKII) facilitates the conversion of glucose to Glu-6-P (glucose 6phosphate) by its enzymatic action in glycolysis. An inhibitor of HKII, lonidamine had
undergone phase III clinical trials, but was unsuccessful due to some toxicities [116]. 2Deoxyglucose (2-DG) is an analog of glucose, which showed anti-cancer effects, but also
increased pro-survival activities [117]. Also, it was reported that during hypoxia, the cells
became chemo-resistant to this drug [118]. Although this drug has not been successful
alone, but in combination has shown promising results in other types of cancer [119,
120].
Two of the most studied drug candidates for cancer prevention are aspirin and
metformin in the recent years. Both these drugs decrease cell proliferation in pancreatic
cancer cells [121]. Some researchers have conducted transcriptomic studies in order to
analyze the gene regulation of these drugs [122]. Also, investigations have been
performed for metabolomic profiling using serum samples from pancreatic cancer
patients and control group. This included mass spectrometry studies to obtain knowledge
about some biomarkers for diagnostic purpose [123]. Moreover, several inhibitors have
been identified in recent years for targeting lactate metabolism. FX-11 is an inhibitor of
lactate dehydrogenase A (LDHA), which has been reported to retard the proliferation of
pancreatic cancer cell lines [124]. Also, several potential mitochondrial activity inhibitors
have been tested for their efficacy, such as: berberine, resveratrol, curcumin and
epigallocatechin gallate [125].
We have evaluated the efficacy of a phytochemical drug for targeting
dysregulated metabolism in pancreatic cancer in this research work, which is described
below.
Steviol
Steviol is plant product from Stevia rebaudiana, with a molecular weight of
318.45 kDa. It is a natural sweetener, which is almost 300 times sweeter than cane sugar.
Several studies have indicated its beneficial properties in being anti-inflammatory, and
anti-hyperglycemic. Reports also suggest its anti-cancer properties in gastrointestinal
cancers and breast cancer [126-129]. However, its role in pancreatic cancer still remains
unidentified.
Steviol is formed through conversion of steviol 16, 17 α epoxide from its
precursor, stevioside, through the bacteria in the human gut [130]. Reports have indicated
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that the precursor molecule, stevioside is very efficient in lowering the blood glucose
levels in humans suffering from diabetes [131], and similar observations were also found
in rats [132]. These reports indicate the efficacy and benefits of this drug for effective
glucose metabolism. The chemical structure of steviol is depicted in Figure 1-13.
In this dissertation, we have evaluated the therapeutic efficacy of this natural
product (Steviol), which suppresses the growth and metastatic phenotypes of pancreatic
cancer (Chapter 4).
Rationale of the Study
Altered glucose metabolic phenotype is a hallmark of pancreatic cancer [133]. It
is essential to identify molecular targets and drugs which can suppress elevated glucose
metabolism. MUC13 protein is a transmembrane glycoprotein (mucin) with high
expression levels in pancreatic cancer. This protein offers fueled tumor
microenvironment to growing cells for adoption of their enhanced tumorigenic behavior
[82, 85]. Some of the mucins such as MUC1 [134, 135] and MUC16 [136] have been
reported to play a significant role in abnormal glucose metabolism. However, the role of
MUC13 in upregulated tumor metabolism had never been investigated earlier. Therefore,
we were interested in deciphering this aspect of MUC13. Further, in order to find some
other molecular targets involved in abnormal cancer metabolism, we found a kinase
protein, Protein Kinase D which had been reported to have an important role in cardiac
glucose uptake leading to hypertrophy [137]. Also, Protein Kinase D1 (PKD1) has been
recognized to have significant role in hypoxic tumor metabolism [138]. Nevertheless, its
involvement in cancer glucose metabolism was never studied. So, it was interesting to
investigate this molecule and the associated signaling mechanisms pertaining to tumor
metabolism. Also, it was mandatory to identify natural agents which could restore
glucose metabolism in pancreatic cancer, with no to minimal side effects. For this,
several compounds were screened, which finally led to the identification of an important
constituent, steviol from the plant Stevia rebaudiana, that could inhibit enhanced glucose
consumption and associated altered metabolism in abnormal cells.
Hypothesis of the Overall Study
Dysregulation of glucose metabolism plays a crucial role in the initiation,
progression and metastatic status in pancreatic cancer. The regulatory factors
(MUC13/PKD1) responsible for deviant glucose metabolism need further investigation in
order to develop effective therapies. Also, we hypothesize that steviol can suppress the
altered glucose metabolism, ultimately leading to less invasive pancreatic cancer.
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Figure 1-13. Chemical Structure of Steviol
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Objective of This Project
To identify the oncogenic proteins involved in metabolic reprogramming of
pancreatic cancer, the underlying mechanisms involved, as well as examining the
potential role of non-toxic natural agents in reducing the elevated glucose metabolism
and its impact on pancreatic cancer.
Specific Aims of the Project
Aim 1: To determine the role of a mucin, MUC13 in glucose metabolism and to
investigate the molecular interactions of MUC13 with the key transporter of glucose,
Glut-1 in pancreatic cancer.
Aim 2: To investigate role of Protein Kinase D1 in glucose metabolism of
pancreatic cancer and the underlying mechanisms.
Aim 3: To investigate the role of a natural agent (Steviol) in glucose metabolism
of pancreatic cancer, and study the mechanistic pathways involved.
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CHAPTER 2.

MUC13 CONTRIBUTES TO REWIRING OF GLUCOSE
METABOLISM IN PANCREATIC CANCER1
Introduction

Pancreatic cancer will be the second leading cause of cancer-related deaths very
soon as per future projections [139]. Due to the late diagnosis, chemo-resistance and
metastasis, 5-year survival rate still remains less than 8% [139]. The pancreas has an
anatomically inaccessible location that prevents routine examination, early stage
diagnosis and timely surgical resection of tumor(s). Additionally, because of highly
aggressive nature, pancreatic cancer cells disseminate rapidly leading to early metastasis
of the disease. At this stage, available treatment options are only moderately successful to
extend the patient’s survival rate. Therefore, it is highly important to understand and
delineate the molecular pathways that lead to increased tumor aggressiveness and poor
patient survival rate. One such unique characteristic physiology of pancreatic tumors
includes a hostile and tumor microenvironment, which favors biochemical and metabolic
adaptations to facilitate pancreatic tumor growth and metastasis. Alterations in metabolic
pathways, which have a common feature of increased glucose uptake and its conversion
to lactate, are highly responsible for cancer progression [140].
Cancer cells undergo an oncogene addiction, which makes them highly dependent
on the activity of an oncogene for survival and proliferation [141]. The fibrotic pancreatic
tumor microenvironment enables pancreatic cancer cells to rely on alternative sources of
nutrients and adapt distinctive approaches to obtain them. Most cancer cells exhibit
enhanced aerobic glycolysis, known as the Warburg effect, an alteration in glucose
metabolism resulting in an acidic tumor microenvironment that facilitates local invasion
of tumor cells [142]. Warburg effect is the enhanced conversion of glucose to lactate
observed in tumor cells, even in the presence of normal levels of oxygen. Glucose is the
major metabolic precursor that supports the Warburg effect and glucose transporter 1
(Glut-1) mediates cellular glucose transport required to fuel anaerobic metabolism in
proliferating cancer cells [143]. The increased lactate production results in enhanced
tumorigenic characteristics such as cell invasion, migration, metastasis of the tumor and
correlates with tumor reoccurrence [144]. Thus, oncogenic networks required for this
process, are highly desirable to develop novel strategies for selective targeting of aberrant
pancreatic tumor metabolism and tumor microenvironment. Pancreatic cancer
metabolism is dramatically rewired by oncogenic KRAS that induces a series of
metabolic alterations, which includes enhanced glycolysis and glutaminolysis, resulting
in enhanced cell growth and proliferation [145]. Hypoxia is one of the factors in the
pancreatic tumors that leads to enhanced glucose metabolism, hypoxia-inducible factor 1
1
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(HIF-1) being an important regulator of cellular oxygen homeostasis [146]. NFκB plays
an important role to regulate the metabolic adaptation in normal and cancer cells by
controlling the balance between the utilization of glycolysis and mitochondrial respiration
[147].
Mucins are a family of high molecular weight and glycosylated proteins that play
significant roles in pancreatic cancer pathogenesis [148]. MUC13 protein, is a
transmembrane mucin, which is aberrantly expressed in pancreatic cancer [82] and
enhances pancreatic tumor progression through various mechanisms; one such
mechanism is being mediated through its interaction with HER2, a member of EGFR
family [83]. In the present study, we report a novel role of MUC13 in metabolic
reprogramming of pancreatic cancer. We demonstrate the metabolic alterations induced
by MUC13 in pancreatic cancer cells and the underlying molecular mechanisms that
drive the associated tumorigenic characteristics. Our studies indicate that the MUC13induced metabolic alterations require NFκB activation that precedes the triggering of
events in controlling glucose metabolism in pancreatic cancer cells. In addition, we
demonstrated the functional interaction of MUC13 and Glut-1 and established their
positive correlation among patient clinical samples belonging to pancreatic ductal
adenocarcinoma. Briefly, our study delineate role of MUC13 in aberrant glucose
metabolism in pancreatic cancer and suggest it as a novel molecular target for therapeutic
intervention of this frightening disease.
Materials and Methods
Cell Culture
MUC13 null pancreatic cancer cells, Panc-1 and MiaPaca (P-V, M-V), and stably
expressing MUC13 (P-M13, M-M13) were used for the study, as described earlier [82].
We also generated MUC13 expressing HPAF-II (sh-V) and knockdown (sh-M13) cells
using a lentiviral transfection, for our study. Cells were maintained in DMEM or
DMEM/F12 media supplemented with 10% fetal bovine serum and 100 µg/ml of G418
antibiotic or 5 µg/ml puromycin. These cells were grown at 37°C in an incubator which
supplied 5% CO2 in a humidified environment.
Clinical Samples
Human pancreatic cancer tissue samples were procured from Baptist Memorial
Health Center. Additionally, cDNA of pancreatic cancer tissue specimens was purchased
from Origene.
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Immunoblotting
Whole cell lysates were prepared followed by immunoblotting as described earlier
[83, 149, 150]. The expression level of several proteins were analyzed using specific
primary antibodies obtained from Cell Signaling: NFҡB p-65 (catalog number: 8242),
phospho-NFҡB p-65, Ser536 (catalog number: 3033), IκBα (catalog number: 4814),
phospho- IκBα, Ser32/36 (catalog number: 8219), Histone H3 (catalog number: 4499),
GAPDH (catalog number: 5174), HIF-1 α (catalog number: 3716), Bcl-2 (catalog
number: 4223), c-Myc (catalog number: 9402), Glut-1 (catalog number: 12939), alphatubulin (catalog number: 2144), p27 Kip1 (catalog number: 2552), Ras (catalog number:
3965), KRAS-12D (catalog number:14429). The anti-MUC13 monoclonal antibody used
for this manuscript was produced in our lab. The secondary antibodies for rabbit (catalog
number: 4011), and mouse (catalog number: 4021) conjugated with horseradish
peroxidase were obtained from Promega.
Reciprocal Co-Immunoprecipitation
The reciprocal co-immunoprecipitation experiments were performed using AsPC1
and HPAF-II cells, which express MUC13. 500µg of protein was used and incubated
with antibodies at 4ºC overnight. Immuno-precipitates were eluted with sodium dodecyl
sulfate sample buffer obtained from Santa Cruz Biotechnology, TX, USA following the
procedures as described earlier [83, 151].
Confocal Immunofluorescence
Confocal immunofluorescence was performed as described earlier [83, 150].
Briefly, cells were fixed and incubated with respective primary antibodies overnight. This
was followed by incubation with Cy3, or Alexa Fluor 488, donkey secondary antibodies
for 1 hour. The images were then captured at 400X magnification using a confocal
microscope (Nikon Corporation, Melville, NY, USA).
Wound Healing /Scratch Assay
Cell migration assay was performed using wound healing assay [149, 152]. Cells
were seeded in 12 well plate at a density of 2x105 cells. The cells were treated with LLactate (2 mM) and 2-Deoxyglucose (10 mM) and further incubated for 24 hours. The
cells were photographed at 0 and 24 h.
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Invasion Assay
Cell invasion assay was performed using BD Biocoat Matrigel Invasion
Chambers (BD Biosciences), as described earlier [149]. Cells were seeded in matrigel
invasion chambers in a serum free medium. The cells were treated with L-Lactate (2
mM) and 2-Deoxyglucose (10 mM) followed by incubation for 24 hours. Then, the cells
were fixed using methanol and were stained with crystal violet. The images were
captured at 24 hours.

Cell Proliferation Assays
Cell proliferation assay was performed in MUC13 null (P-V) and MUC13
expressing (P-M13) cells after treatment with lactate (2 mM) and 2-DG (10 mM). The
experiment was terminated after 48 hrs with the addition of 20 µl of tetrazolium dye,
MTT reagent: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazol-2-yl)-2,5-diphenyltetrazolium bromide. After 2 hrs, 100 µl of dimethyl sulfoxide was added to the
cells and was kept on shaker for 10 minutes. Finally, the absorbance was recorded at 570
nm, and the percentage cell viability was quantified.
Lactate and Glucose Assays
Lactate and Glucose assays were performed using kits from Cayman Chemicals
(Lactate assay kit catalog number: 600450, Glucose assay kit catalog number:
10009582). MUC13 expressing and null cells were seeded (104 cells/ well in 96 wells
plate) and media collected to measure the amount of lactate after 24 hours, and unused
glucose levels after 48 hours. The samples were analyzed according to the instructions
provided in the kit, the readings were recorded and calculations were done.
Isolation of RNA and Polymerase Chain Reaction (PCR)
RNA from pancreatic cancer cells and tissues was isolated using Qiagen kit and
quantified using Nanodrop instrument 2000 (Thermo Scientific). RNA (2 µg) was reverse
transcribed using SYBR green RNA Reverse Transcription kit. The expression of genes
was determined by using specific primers by qPCR and semi quantitative PCR. GAPDH
was used as an internal control for the reactions.
In Situ Proximity Ligation Assay (PLA)
This assay was performed using the Duolink Red Starter PLA Kit as described
earlier [83] to detect the subcellular localization of the protein-protein interaction at a
single-molecule resolution. Briefly, oligonucleotide-conjugated anti-mouse minus and
anti-rabbit plus PLA secondary probes were added and incubated in a humidified
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chamber for 1 hour at 37 ºC. The oligonucleotides were ligated for 30 minutes at 37 ºC to
produce rolling circle amplification products tagged with a red fluorescence probe.
Further, the nuclei were counterstained with 4’, 6-diamidino-2-phenylindole (DAPI), and
were then visualized using a Zeiss confocal microscope.
Co-Capping Assay
This assay was performed using MUC13-expressing HPAF-II and AsPC1 cells as
described before [83]. The cells were incubated with NHS-Rhodamine-labeled antiMUC13 mAb (30µg/ml) for 1 hour at 4 ºC, and plated for adherence at 37 ºC for about 2
hours. The cells were incubated with Glut-1 (Cell Signaling, catalog number: 12939), or
α-tubulin negative control (Cell Signaling, catalog number: 2144), overnight. Cells were
further incubated with Alexa-Fluor 488 anti-Rabbit secondary antibody, and the images
captured using 710 Zeiss confocal microscope [150].

Statistical Analysis
The data in this manuscript were evaluated and analyzed using Microsoft excel
software, and the statistical analysis is represented as means+/-SEM of three independent
experiments. In all cases, the significance of the data was analyzed through unpaired twosided Student’s t test, and p-value less than 0.05 was considered statistically significant.
Results
MUC13 Enhances Glucose Metabolism and Invasiveness in PDAC Cells
Processes in malignant transformation involve enhanced glucose uptake and
lactate production which consequently lead to the defects in the expression of glycolytic
enzymes and metabolite transporters and in oncogenic alterations [153]. In order to
investigate the role of MUC13 on glycolytic properties of pancreatic cancer cells, glucose
and lactate assays were performed in MUC13 null Panc-1/MiaPaca cells (P-V/M-V) or
stably MUC13 overexpressing (P-M13/M-M13) cells. We observed significantly
(p<0.05) higher upregulation of L-lactate production and glucose consumption in
MUC13 expressing cells as compared to MUC13 null control cells (Figure 2-1A,.B).
Therefore, our results demonstrate that MUC13 enhances glucose metabolism of
pancreatic cancer cells. Previous reports demonstrate that MUC13 enhances invasion and
migration in pancreatic cancer cells. In this study, our observations suggest that MUC13
expression modulates glucose consumption in PDAC cells, therefore, we sought to
investigate if MUC13 induced changes in proliferation, invasion and migration are
mediated through altered glucose metabolism. We demonstrate that MUC13 expression
(P-M13 and M-M13) cell invasion (Figure 2-1C, D) and migration (Figure 2-1E, F) that
can be further enhanced by adding lactate (2mM), an end product of aerobic glycolysis,
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Figure 2-1. MUC13 Enhances Glucose Metabolism in PDAC Cells
Expression of MUC13 shown by Western blotting, lactate and glucose assay in MUC13
null Panc-1 (P-V) and stably expressing MUC13 (P-M13) cells (A) and in MUC13 null
MiaPaca (M-V) and stably expressing MUC13 (M-M13) cells (B). Invasion assay
performed in P-V and P-M13 (C) and M-V and M-13 cells (D) after treatment with
lactate (2 mM) and 2-DG (10 mM). Images were captured after 24 hrs and the relative
number of invasive cells was quantified. Wound healing (scratch) assay performed in PV and P-M13 (E) and M-V and M-13 cells (F) after treatment with lactate (2 mM) and 2DG (10 mM). The images were captured at 0 hrs and 24 hrs. n=3; *p<0.05.
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to the media in which cells are cultured. This effect, however, was abrogated by inducing
glucoprivic conditions using 2-Deoxyglucose (2-DG, 10mM) (Figure 2-1C through F).
These results suggest that MUC13 influenced metastatic characteristics of PDAC cells
are partly the consequence of its modulation of the glucose metabolism.
MUC13 Upregulates c-Myc Expression and the Downstream Effectors of Glucose
Metabolism
Since our results showed a marked upregulation of glucose uptake and lactate
production, we evaluated effects of MUC13 expression on the important proteins
involved in enhanced cancer cell metabolism. Immunoblotting and immunofluorescence
analysis demonstrated an enhanced expression of c-Myc (Figure 2-2A, B). c-Myc is a
master regulator of downstream processes that are involved in cell growth and
metabolism [56]. The changes in c-Myc expression were accompanied by overexpression
of glucose transporter1 (Glut-1), which ensures accumulation of glucose in the cell and
secretion of lactate out of the cell (Figure 2-2A, B). Also, we observed that KRAS levels
were induced in MUC13 expressing cells. This KRAS has prominence in regulating
anabolic glucose metabolism [145]. One of the mediators of KRAS-induced
transcriptional changes of metabolic genes is known to be HIF-1α, and its expression was
found to be significantly higher upon MUC13 expression (Figure 2-2A, B) [145]. The
mean fluorescence intensities for c-Myc, Glut-1 and HIF-1α were also quantified using
Zen software (Supplementary Figure S4 A and B). Additionally, MUC13 expressing cells
were found to modulate proteins associated with cell death such as activation of antiapoptotic protein, Bcl-2 and inhibition of tumor suppressor/cell cycle inhibitor, p27
(Figure 2-2A). Immunoblotting and Immunofluorescence results were confirmed using
qPCR analysis (Figure 2-2C) and semi-quantitative PCR (Figure 2-2D) showing
increased mRNA expression of c-Myc, Glut-1 and HIF-1α in MUC13 expressing Panc-1
and MiaPaca cells which was inhibited on MUC13 knockdown in HPAF-II cells (shMUC13). The activation of HIF-1α prompted us to investigate whether MUC13 typically
demands hypoxic environment to contribute to adaptive mechanisms of enhanced cell
metabolism. Our results showed that the induced hypoxic conditions accompany
enhanced production of lactate in MUC13 expressing cells as compared with MUC13
null cells (Figure 2-2E). The nuclear localization of c-Myc in MUC13 expressing Panc1 and MiaPaca cells (P-M13/M-M13) and the cellular localization of Glut-1 has been
illustrated through confocal microscopy (Figure 2-3). Also, the localization of HIF-1 α
protein in pancreatic cancer cells has been demonstrated by immunofluorescence
techniques (Figure 2-4). These results indicate that MUC13 contributes to survival
adaptation in hypoxic environment leading to enhanced metabolic changes for the
survival of pancreatic cancer cells. This data suggest MUC13 expression induce rewiring
of oncogenic signaling pathways that contribute to adaptive cellular mechanisms in tumor
microenvironment.
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Figure 2-2. MUC13 Regulates Protein and mRNA Expression of Key Factors
Involved in Glucose Metabolism
(A) Western blot showing the expression level of indicated proteins involved in glucose
metabolism. Whole cell lysates were collected from cells and the levels of protein
expression were determined. (B) Densitometric analysis of bands for c-Myc, Glut-1 and
HIF-1α. n=2; *p<0.05. (C) qPCR depicting changes in mRNA expression in MUC13 null
(P-V/M-V) cells and MUC13 expressing (P-M13/M-13) Panc-1 and MiaPaca cells;
MUC13 expressing (sh-V) and knockdown (sh-M13) HPAF-II cells, *p<0.05. (D) Semiquantitative PCR performed to determine the expression of HIF-1 α and Glut-1 on
MUC13 expression in PanCa cells and bars representing relative quantification of HIF-1α
and Glut-1 expression. (F) Lactate assay performed in Panc-1 cells under normoxic and
hypoxic conditions. *p<0.05.
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Figure 2-3. MUC13 Enhances Expression of c-Myc and Glut-1 in Cells
Confocal microscopy images showing the expression of (A) c-Myc and (B) Glut-1 in
indicated cells. Cells were seeded in 4-well chambered slides, fixed, permeabilized and
stained with respective antibodies. The slides were further processed and analyzed for
confocal microscopy. Images were captured at 400X. DAPI was used as a counter stain
for the nucleus.
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Figure 2-4. MUC13 Enhances Expression of HIF-1α in Cells
Confocal microscopic images showing the expression of HIF-1 α in indicated cells. Cells
were seeded in 4-well chambered slides, fixed, permeabilized and stained with HIF-1 α.
The slides were analyzed for confocal microscopy. DAPI was used as a counter stain for
the nucleus.
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MUC13 Expression Leads to the TNF-Induced Activation/Nuclear Shuttling of
NFҡB p-65
We further wanted to investigate the signaling pathways that might be involved in
the MUC13 influenced aberrant glucose metabolism in pancreatic cancer cells. Our
results demonstrate that MUC13 expression facilitates TNF-induced activation/phosphorylation of NFҡB-p65 at Ser536 and its nuclear translocation in Panc-1 and
MiaPaca (P-M13 and M-M13) cells. Although, TNF-α induced p65 nuclear accumulation
(0-30 min) was also observed in vector control cells (M-V and P-V), but a remarkable
increase was observed upon MUC13 expression (M-13 and P-M13), suggesting its
involvement in the MUC13 mediated signaling mechanisms (Figure 2-5A). These events
were observed with concomitant degradation/decrease in the expression levels of IκBα
(NFҡB repressor) in the cytoplasm, which is ultimately known to release its inhibition
from NFҡB p-65 Western blotting depicting the effect of p65 silencing on the
metabolism involved proteins in presence of TNF-α stimulation (5 ng/ml for 24 hours)
accumulation and phosphorylation of NFҡB p65 (Figure 2-5B) and accompany its
translocation to the nucleus [154]. Similar results were corroborated on MUC13
knockdown in HPAF-II cells, which indicated decreased nuclear (Figure 2-5C) as well
as cytoplasmic IκBα degradation in MUC13 knockdown cells (sh-M13) (Figure 2-5D).
These results suggest the association of MUC13 to the promotion of TNF-α induced
NFҡB activation. These results indicate that MUC13 induces NF-κB activation, which is
independent of the mode of stimulation and may involve distinct mechanisms
augmenting NF-κB activation. One such mechanism may be similar to the one discussed
previously in colon cancer, which suggests the role of MUC13 in augmented recruitment
of cIAP1 to the TNFR/RIPK1 complex, and promotion of RIPK1 ubiquitination by
cIAP1, which ultimately leads to NFκB activation and downstream NFκB-regulated gene
expression [155]. We then examined whether TNF-α-induced IκBα degradation is due to
IκBα phosphorylation, and used a proteasome inhibitor, MG132 to block IκBα
degradation. Western blotting analysis revealed TNF-α induced phosphorylation/degradation of IκBα only in MUC13 expressing cells (M-M13) but not in vector control
cells (M-V) (Figure 2-5E), which was further restored on MG132 treatment. These
results confirm the role of MUC13 in the induction of NFҡB activation via IκBα
phosphorylation and degradation.
In order to determine if NFҡB is required for MUC13 mediated alteration of
glucose metabolism, we examined the expression of important proteins involved in
regulation of glucose metabolism on silencing p65 in MUC13 null or stably expressing
MiaPaca cells. Following TNF-α exposure for 24 hours, MUC13 expressing cells
exhibited increased expression of c-Myc, HIF-1α, Bcl-2, and Glut-1 as compared to
MUC13 null cells. This increase however, was repressed by silencing of p65 (Figure
2-5F). Also, we demonstrated that presence of MUC13 leads to the okadaic acid (another
inducer of NFҡB) led to the nuclear translocation of NFҡB p-65 (Figure 2-6). These
results altogether suggest that NFҡB is required for MUC13 induced expression of
proteins associated with enhanced glucose metabolism in pancreatic cancer cells.
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Figure 2-5. MUC13 Expression Leads to Enhanced Activation/Nuclear
Translocation of NFҡB p-65
(A) Western blots showing the expression level of p65 and phospho-p65 in M-V/M-M13
and P-V/P-M13 cells. Cells were spiked with TNF-α at a concentration of 20 ng/ml for 0,
10 and 30 minutes, and the nuclear extracts prepared. Histone H3 served as the internal
control. (B) Western blots indicating changes in the expression of IκB α shown in the
cytoplasmic extracts in aforementioned cell lines. (C and D) Western blots showing the
expression level of p65, phospho-p65 and IκB α in the nuclear and cytoplasmic extracts
of MUC13 expressing (sh-V) and MUC13 knockdown (sh-M13) HPAF-II cells. (E)
Western blotting depicting the degradation of pIκB α and IκB α after treatment with
MG132 (1 hr, 10 µM) in presence of TNF-α stimulation (20 ng/ml, 30 minutes) (F)
Western blotting depicting the effect of p65 silencing on the metabolism involved
proteins in presence of TNF-α stimulation (5 ng/ml for 24 hours) (G) Schematic
representation depicting an activation of NFκB on IκB phosphorylation in presence of
MUC13 following TNF-α or okadaic acid stimulation.
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Figure 2-6. MUC13 Expression Leads to the OA-Induced Activation/Nuclear
Translocation of NFҡB p-65
(A) Western blots showing the expression level of IκB α in cytoplasmic lysates from
MiaPaca (M-V/M-M13) cells. Cells were stimulated with Okadaic acid at indicated
concentrations (0, 50 and 100 nM) for 4 hours. (B) Western blots showing the expression
level of p65 and phospho-p65 in the nuclear lysates of aforementioned cells. Histone H3
served as the internal control.
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MUC13 Interacts with Glut-1 and This Interaction Is Disrupted by NFҡB Inhibition
Our results demonstrate increased Glut-1 expression in Panc-1 and MiaPaca cells
while MUC13 is exogenously overexpressed, thus it is warranted to investigate molecular
cross talk between these proteins. Our investigations revealed a direct molecular
interaction of MUC13 with Glut-1 in PDAC cells as demonstrated by multi-level
experimental techniques, such as reciprocal co-immunoprecipitation (co-IP), proximity
ligation assay (PLA), co-capping and co-localization assays (Figure 2-7A through F).
Results from reciprocal co-IP showed that MUC13 and Glut-1 remains in a
molecular complex. This interaction stabilizes Glut-1 as demonstrated by cycloheximide
chase assay with half-life as low as 1 hr in MUC13 null P-V cells and greater than 3
hours in MUC13 expressing P-M13 cells (Figure 2-7C. D).
Proximity ligation assay demonstrated that the interaction between these proteins
is direct as both proteins exist in a close proximity as indicated by multiple red spots on
the cell surface (Figure 2-7E). MUC13 with HER2 serve as an experimental positive
control in PLA as they are reported to physically interact in PDAC cells. Additionally,
co-capping assay showed a progressively increasing distribution of both MUC13 and
Glut-1 staining into membrane caps which strongly suggests their co-clustering (yellow
color) and molecular interaction in PDAC (Figure 2-7F). Co-capping experiment,
performed with α-tubulin in HPAF-II cells, did not show any clustering with MUC13,
and served as negative experimental control. We further confirmed our observations
through confocal immunofluorescence utilizing antibody-mediated double
immunofluorescence staining technique. Results of this analysis showed strong colocalization (yellow color) of MUC13 and Glut-1 in both HPAF-II and AsPC1 cells
(Figure 2-8A). Interestingly, this co-localization was abrogated upon treatment with a
pharmacological inhibitor of NFҡB, sulphasalazine (Figure 2-8B). Sulphasalazine is
known to inhibit NFҡB activation/translocation to nucleus via direct inhibition of enzyme
IҡB kinase (IKK) that phosphorylates/inhibits NFҡB repressor, IҡBα [156]. Similar
results were obtained in reciprocal co-IP in which MUC13 expressing PDAC cells failed
to form MUC13-Glut-1 molecular complexes in presence of sulphasalazine (Figure
2-8C, D). We further sought to investigate whether the interaction between the two
proteins and NFҡB activation influence MUC13 mediated altered glucose metabolism in
PDAC cells. We observed reduced lactate production in MUC13 expressing cells on
treatment with sulphazalazine (Figure 2-8E). These results imply that molecular
interaction between MUC13 and Glut-1 is mediated through NFҡB activation and
suggest the role of MUC13 in glucose metabolism via alteration of Glut-1 functionality in
PDAC cells.
MUC13 and Glut-1 Expression Directly Correlate in Pancreatic Cancer Tissues
To understand clinical correlation of MUC13-Glut-1 molecular interaction, we
examined human pancreatic cancer tissues for MUC13 and Glut-1 expression using
qPCR technique (Figure 2-9 A, B). Two independent sets of samples were utilized for
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Figure 2-7. MUC13 Interacts with Glut-1 Protein
(A and B) Reciprocal co-immunoprecipitation assay performed between MUC13 and
Glut-1 using whole cell protein lysates from MUC13 expressing, AsPC1 and HPAF-II
cells. (C) Cycloheximide chase assay depicting the stability of Glut-1 in P-V and P-M13
cells. Cells were treated with cycloheximide (10μM) at different indicated time points
followed by lysate preparation and Western blotting. Alpha-tubulin (α-tubulin) served as
an internal control. (D) Bars representing relative quantification of the blots. (E) In situ
proximity ligation assay (PLA) performed using HPAF-II cells with the Duolink Red
starter kit. DAPI was used as a counter stain for the nucleus. MUC13/Her2 served as
positive control, and MUC13 alone as negative control. The co-localization between
MUC13/Glut-1 and MUC13/Her-2 has been indicated by arrows. (F) Co-capping assay to
demonstrate interaction between MUC13 and Glut-1 in HPAF-II and AsPC1 cells.
HPAF-II cells with anti-α tubulin is a negative control for this experiment. Images were
captured at 400X.
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Figure 2-8. MUC13-Glut-1 Interaction is Disrupted by Sulfasalazine
(A) Confocal immunofluorescence of MUC13 and Glut-1 in MUC13 expressing, HPAFII and AsPC1 cells depicting co-localization (yellow color). Cells were cultured in 4-well
chambered slides, fixed, permeabilized, stained with indicated antibodies and analyzed
for confocal microscopy. DAPI was used as a counter stain for the nucleus. (B) Cells
were treated with sulphasalazine (0.9 mM) for 24 hrs and processed for immunostaining
and confocal microscopy. Images were captured at 400X. (C and D) Reciprocal coimmunoprecipitation assay between MUC13 and Glut-1 performed using protein lysates
from HPAF-II cells. Cells were treated with sulfasalazine (0.9mM) for 24 hours and
protein lysates prepared. The immunoprecipitates were resolved on a 10% gel, and
followed by immunoblotting with anti-MUC13 and anti-Glut-1 antibodies. (E) Lactate
assay was performed in MUC13 expressing and null cells after treatment with or without
sulfasalazine. Cell culture media was collected after 48 hours to measure the amount of
L-Lactate concentration using lactate assay kit.
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Figure 2-9. MUC13 and Glut-1 Expression Directly Correlate in Human
Pancreatic Cancer Tissues
(A) qPCR was performed to analyze the levels of MUC13 and Glut-1 using RNA from
freshly collected human PDAC tissues (N=8) procured from Baptist Memorial hospital,
Memphis. (B) and cDNA from PDAC tissues (N=6) procured from Origene. The
correlation coefficient (r) and coefficient of determinations (r2) were 0.982 and 0.862
respectively. The analysis was performed by graph pad prism software. (C) Schematic
representation for the mechanism of MUC13 mediated glucose metabolism.
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the experiment, which include freshly collected RNA from PDAC tissue samples (N=8)
procured from Baptist Memorial hospital, Memphis (Figure 6A); and cDNA (N=6)
procured from Origene (Figure 2-9B). Analysis of MUC13 and Glut-1 expression in both
the sets revealed a positive correlation between the expressions of these genes in human
pancreatic cancer tissues. All tissue samples were positive for MUC13 and Glut-1, which
showed a similar trend in the expression levels. The correlation coefficient (r) and
coefficient of determinations (r2) were 0.982 and 0.862 respectively. The analysis was
done using graph pad prism software.
Discussion
High cellular glucose metabolism has been recently recognized as one of the
hallmarks of cancer. Pancreatic cancer cells especially are highly active metabolically
and programmed for extensively higher consumption of bio-fuels to operate oncogenic
machinery. Increased glucose consumption of pancreatic cancer cells to meet the
pathological requirements is supported by Warburg effect. This rewired metabolism is
acquired to support their rapid proliferation and metastasis across the body. Although,
several oncogenes and tumor suppressors are known to facilitate the metabolic adaptation
in pancreatic cancer [157], investigation of novel molecular targets and their mechanisms
are highly essential to improve treatment outcomes of this highly dreadful disease. In this
study, we observed the mechanistic role of MUC13 as an oncogenic molecular target that
modulates glucose metabolism in pancreatic tumor cells. Our study provides the first
evidence for the critical involvement of MUC13 in metabolic reprogramming of
pancreatic cancer cells by activating the NFκB survival pathway and molecular
interaction with Glut-1 receptor.
Our results demonstrate molecular mechanisms that drive the glycolytic
phenotype conferring growth advantage to pancreatic cancer cells. This signifies a critical
role of MUC13 in tumor microenvironment favoring the development of a more
aggressive and invasive phenotype. Our study presents three important conclusions
implicating the mechanisms that stimulate increased glucose metabolism and lactate
production in pancreatic tumors. Our data firstly demonstrates that MUC13 expression
alters the metabolic phenotype of pancreatic cancer cells and influences their
proliferation and invasiveness due to enhanced lactate secretion. This as a result, provides
an acidic tumor microenvironment, that contributes to highly aggressive and metastatic
behavior of cancer cells via influencing a number of oncogenic signaling pathways,
including the activation of proteins that regulate glucose transport [158]. One such main
protein is Glut-1, which represents a potential therapeutic target and its expression level
is altered with MUC13 expression. 2-Deoxyglucose, a metabolic inhibitor of Glut-1
receptors, inhibits up to 59-95% growth of PDAC cells [159]. HIF-1α levels in MUC13
expressing cells increase under normoxic and hypoxic environments accompanied by
increase in lactate production. These results suggest that MUC13 induced altered glucose
metabolism involves the activation of important proteins, such as Glut-1 and HIF-1α,
which may be contributing to MUC13 mediated adaptive cellular mechanisms in tumor
microenvironment to maintain a glycolytic phenotype. Secondly, our investigations
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reveal MUC13 induced activation of NFκB survival pathway, which triggers a number of
key proteins involved in altered glucose metabolism. Enhanced IҡBα degradation and
activation/nuclear translocation of NFκB in MUC13 expressing cells was observed
following TNF-α or okadaic acid stimulation. These events were typically accompanied
by activation of c-Myc, HIF-1α and Glut-1 expression levels that are observed to be
abrogated specifically in MUC13 cells following silencing of NFκB. Our data indicates
that the metabolic events controlled by MUC13 occur following NFκB activation.
MUC13 has been recently reported to functionally interact with HER2 and this
interaction mediates MUC13 induced pancreatic cancer progression. This study
elucidated a novel, MUC13-Glut-1 interaction that may be one of the important events in
driving mechanisms of aberrant glucose metabolism in pancreatic cancer cells. We found
that the interaction between MUC13 and Glut-1 is governed by constitutive NFκB
activation. MUC13 interaction stabilizes Glut-1 as suggested by increased half-life of
Glut-1 in MUC13 expressing cells compared to MUC13 null cells. Interaction between
these two proteins appears to be direct and in very close proximity, as evident by co-IP
and PLA assays, respectively. Since MUC13 and Glut-1 complex is dependent on nuclear
translocation of NFκB as it is prevented by sulphasalazine treatment, suggest an
opportunity to develop novel therapeutic strategies to attenuate aggressive/metastatic
behavior of pancreatic cancer cells. However, it also leads to questions, as to how NFκB
activation promotes interaction between MUC13 and Glut-1, and which specific domains
of both proteins are involved in this molecular interaction. Although, further
investigations are warranted, we speculate that a cytoplasmic domain of MUC13 binds to
Glut-1, as cytoplasmic domain of MUC13 is suggested to have role in cell signaling
[160]. A positive correlation between the expression of MUC13 and Glut-1 in human
pancreatic cancer tissues suggest clinical correlation of our proposed novel mechanism
related to aberrant glucose metabolism in pancreatic tumors.
In summary, this study revealed a novel role of MUC13 in rewiring of a distinct
glucose metabolic network that drives favorable tumor microenvironment and oncogenic
signaling pathways in pancreatic cancer cells for the adoption of their enhanced
tumorigenic and metastatic behavior. Thus, inhibition of MUC13 via conventional
pharmacological agents and/or non-conventional siRNA/miRNA mediated technologies
can selectively suppress pancreatic tumor growth and metastasis via inhibition of
glycolytic influx in pancreatic cancer cells. Our observations suggest that the reliance of
pancreatic tumor growth and metastasis on MUC13-Glut-1 mediated glucose metabolism
can be exploited for the development of novel targeted therapeutic strategies for
pancreatic cancer. Finally, our study offers a very promising target for therapeutic
manipulation via disabling aberrant glucose metabolism in pancreatic cancer patients,
thereby prolonging survival rate of patients suffering from this dreadful disease. Next, it
was essential to identify other molecular targets which are involved in metabolic
reprogramming leading to invasive pancreatic cancer. In this regard, we further
investigated the role of another protein, Protein Kinase D1 (PKD1), in aberrant glucose
metabolic network in pancreatic cancer, which has already been reported to have a role in
pancreatic tumorigenesis.
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CHAPTER 3. PROTEIN KINASE D1 INDUCES METABOLIC SWITCH IN
PANCREATIC CANCER VIA MODULATION OF MAMMALIAN TARGET OF
RAPAMYCIN
Introduction
Pancreatic cancer is a highly malignant disease, and prevalent in the United States
that ranks third in mortality rates related to cancer [1]. The lack of early detection,
chemoresistance and increased metastasis contributes to the highly aggressive behavior of
this disease and poor survival rate [1]. Therefore, it is essential to investigate and
comprehend mechanisms that lead to the tumor aggressiveness and chemoresistance in
pancreatic cancer. One such unique characteristic physiology of pancreatic tumors
includes a hostile and tumor microenvironment, which favors biochemical and metabolic
adaptations to facilitate pancreatic tumor growth and metastasis. The metabolic
alterations enable cells to satisfy their bioenergetics needs by adapting to the changing
environments for survival, longevity and availability of nutritional requirements[161].
Cellular signaling empowers cancer cells to acquire and process nutrients in a manner
favorable to proliferation than production of ATP [162]. Through aerobic glycolysis,
cancer cells produce energy by converting glucose into lactate, in presence of oxygen,
which results in enhanced synthesis of lipids and nucleotides and stimulates growth and
invasion. Herein, we postulate that the identification and strategic targeting of molecules
that regulate altered glucose metabolism can help in the effective maintenance of the
disease and development of therapeutics.
Protein Kinase D1 (PKD1), a serine-threonine kinase, is an important modulator
of several kinase signal transduction pathways [163]. PKD1 belongs to the PKD family
and is the most studied protein among the three family members (PKD1, PKD2 and
PKD3) [163]. Previous reports have suggested that PKD1 is involved in pancreatic
cancer pathogenesis [88, 164], but the underlying signaling mechanisms are largely
unknown. Studies have suggested the role of PKD1 in increasing pancreatic cancer
proliferation and growth rate through stimulation of NFκB, an important transcription
factor involved in various cellular mechanisms [165]. PKD1 has also been reported to be
involved in the Notch pathway being downstream of KRAS, leading to pancreatic
neoplasia [164]. PKD1 also regulates the duct formation leading to pancreatic cancer
initiation and growth [166]. PKD1 acts as one of the reactive oxygen species (ROS)
sensing molecule, increases oxidative stress, ultimately resulting in pancreatic cancer
progression [88]. Therefore, we were interested to investigate the mechanisms by which
PKD1 may contribute to pancreatic tumorigenesis and understand the signaling processes
involved therein.
One of the most important pathway regulating metabolic processes is mTOR
(mammalian target of rapamycin) pathway [167]. mTOR is a serine/threonine kinase that
exists as two different complexes, mTORC1 and mTORC2. mTOR, in association with
raptor and mLST8 forms mTORC1, regulates protein translation, cell-cycle progression
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and metabolism [161]. While, mTOR, in association with Rictor (rapamycin insensitive
companion of mTOR) and mSIN1 (stress-activated protein) forms mTORC2 and
regulates cell survival/glucose metabolism and cytoskeletal remodeling [167].
Rapamycin is known to inhibit mTORC1 activity and promotes β-oxidation for anabolic
storage pathways.
Therefore, in this study we suggest a novel role of PKD1 in regulating glucose
metabolism in pancreatic cancer, which drives pancreatic tumorigenesis, chemoresistance
and progression. This takes place in correlation with mTOR signaling, wherein mTORC1
predominantly regulates PKD1 induced metabolic changes. Briefly, our study prospects
PKD1 as a novel molecular target in pancreatic cancer for therapeutic intervention.
Materials and Methods
Cell Culture
Pancreatic cancer cells, HPAF-II/BxPC3 (low PKD1 expression); Panc1/AsPC1/Capan-1/MiaPaca (high PKD1 expression) were used for this study. All cells
were maintained in DMEM/F12 or RPMI media containing 10% fetal bovine serum in an
incubator at 37ºC temperature with 5% CO2. The normal human pancreatic cell line,
HPNE, was maintained in DMEM media. The complete media, and the cell lines were
maintained. The cells were frequently investigated for mycoplasma growth and
contamination.
Procurement and Scoring of Human Pancreatic Cancer Tissues for Analysis of
PKD1 Expression
Pancreatic cancer tissue microarray from US Biomax (# BIC14011a SL160) with
chronic pancreatitis (n=12), PanIN-1 (n=10), PanIN-2 (n=8) and PDAC (n=8). Also,
normal (n=3) tissues were obtained from Baptist Memorial Hospital (BMH), Memphis,
TN. The scoring of the PKD1 expression was performed as described earlier in detail
[84] . Stained slides were digitally scanned and analyzed for PKD1 staining at the
UTHSC Pathology Department. Captured images were independently analyzed and
scored by three reviewers, who were kept blinded to the patient history. The intensity of
immunoreactivity of PKD1 was graded on a 0 to 4 scale (0 for no staining, 1 for weak
immunoreactivity; 2 for moderate immunoreactivity; 3 for strong immunoreactivity, and
4 for very strong immunoreactivity). The percentage of cells positive for PKD1
immunoreactivity within the tumor and normal tissue sections were scored as follows: 0–
25% as 1, 26–50% as 2, 51–75% as 3 and 76–100% as 4. The mean composite score
(MCS) was determined by calculating an average of the composite scores (intensity x
percentage) of respective samples in each category.
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Western Blotting
The whole cell lysates from pancreatic cancer cells were prepared and used for
investigating the changes in protein expression through Western blotting procedure, as
described before [11, 168]. Briefly, 40µg of protein was loaded per well to perform SDS
PAGE followed by Western blotting. The transfer of gels was done on PVDF
(polyvinylidene difluoride) membrane and membranes blocked in either 5% non-fat dairy
milk or 5% BSA (bovine-serum albumin for 1 hour followed by incubation with the
primary antibodies overnight at 4ºC. The primary antibodies with the following catalog
numbers were procured from Cell Signaling Technology: HIF-1 α (3716), Glut-1
(12939), Ras (3965), KRAS-12D (14429), eIF4e (9742S), peIF4e (9741S), 4EBP1
(9452S), p4EBP1 (2855S), mTOR (4517S), and p-mTOR (5536S). Beta-actin antibody
was obtained from Sigma (A2228). The rabbit (4011), and mouse (4021) secondary
antibodies were purchased from Promega company.
Immunofluorescence
Immunofluorescence was conducted as described earlier [150]. Briefly, cells were
fixed, permeabilized and incubated overnight with primary antibodies. Following day, the
cells were incubated with respective secondary antibodies for 1 hour, washed and
mounted. Further, the images were taken under a confocal microscope at 400X
magnification (Zeiss 710, Germany).
Immunohistochemistry
Pancreatic cancer human tissues microarrays were obtained from Baptist
Memorial Hospital, Memphis and were immunostained using antigen-retrieval method,
as described earlier [84] using commercially available Biocare kit from Biocare Medical,
CA, USA,. Briefly, the tissue slides were deparaffinized, rehydrated, peroxidized and
antigen retrieved. Further, the tissues were incubated with primary antibodies overnight
followed by addition of secondary MACH4 Universal HRP mouse polymer (#M4U534H)
followed by staining with 3-diaminobenzidine (DAB) chromogen (#DB801) and
counterstaining with hematoxylin. The slides were then subjected to dehydration steps
and mounting [83].
Transfection of Cells
Pancreatic cancer cells having low PKD1 expression (HPAF-II and BxPC3) were
incubated in serum-free OPTI-MEM media overnight, and transiently transfected with
PKD1 expression plasmid and control pEGFP using Lipofectamine 2000 reagent.
Following six hours of transfection, 10% serum-containing regular media was added to the
cells after removing the old media. The transfection procedure was terminated after 48
hours and the cells were used for further experiments.
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Lactate Assay/ Glucose Assay
Lactate and Glucose assays were performed by utilizing commercially available
kits from Cayman Chemicals (lactate assay kit: catalog No.: 600450 and glucose assay
kit: catalog No. 10009582). Cells were seeded as per the manufacturer’s instructions in
the kit, and media of cells was used to determine the amount of lactate production and
glucose consumption upon termination of the experiment at 24 and 48 hours. Further, the
absorbance was recorded at the indicated wavelength, and readings were
analyzed/calculated.
Cell Migratory Assay
The cell migration assay was conducted using Boyden chamber plate [11, 169,
170]. 50,000 pancreatic cancer cells were seeded on the top chamber of the 96 well plate
in a serum-free media, and 250µl of serum-containing media was added to the lower
chamber. L-Lactate (2 mM) or 2-Deoxyglucose (10 mM) were added to the cells, which
was followed by incubation for 18 hours at 37ºC. Thereafter, the cells were fixed with 4%
paraformaldehyde, stained with crystal violet and washed with water. The images of cells
were captured after complete drying of the plate.
Cell Invasion Assay
Cell invasion assay was performed using Matrigel Invasion Chambers from BD
Biosciences [149]. 25,000 cells were seeded in the chambers containing media without
serum in the upper chamber and complete media (10% FBS) in the lower one. L-Lactate
(2 mM) or 2-Deoxyglucose (10 mM) were added to the cells, which was followed by
incubation for 24 hours at 37ºC. Further, the cells were fixed with methanol and crystal
violet stained. The plates were washed with water and left to dry, which was followed by
capturing images.
Cell Proliferation Assay by MTT
MTT assay was performed in PKD1 expressing and null cells to determine the
effect of PKD1 in cell proliferation as described before [11]. Following 48 hours, 20 µl
MTT reagent was added to the cells. Then, 2 hours after the addition of this reagent, 100
µl of dimethyl-sulfoxide (DMSO) solution was added on top of the cells and the plate
was subjected to vigorous shaking for another 10 minutes. Next, the absorbance was read
at a wavelength of 570 nm, the cell viability was calculated and graph was plotted.
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Clonogenic Studies
The pancreatic cancer cells were seeded in 12-well plate (250 cells/well). The
cells were subjected to both normoxic and hypoxic conditions at the same time. The
experiment was terminated after 7 days, after PBS wash, adding fixative (cold methanol)
for 10 minutes, and staining by crystal violet. This was followed by removal of stain,
washing with water, drying of plate and capturing images.
Gene Expression Studies
RNA samples were isolated from various pancreatic cancer cells using Qiagen kit.
The reaction was conducted as described earlier [11]. The concentration of samples was
determined and 2 µg of RNA was reverse transcribed. The expression of genes (PKD1,
HIF-1α and Glut-1) was determined by precise primers through real-time PCR
experiment. GAPDH served as an internal control.
Statistical Analysis
The significance of the data in this manuscript was determined through Student’s t
test, and p-values below 0.05 was set to be statistically significant.
Results
PKD1 Is Overexpressed in Human Pancreatic Cancer Tissues and Cells
The expression profile of PKD1 in human pancreatic cancer versus normal
pancreatic cells was investigated using immunohistochemistry technique. PDAC and
normal pancreas tissues were immuno-stained for PKD1 and scored. We evaluated the
staining scores in MCS (mean composite score) taking in account of average staining
pattern. Normal pancreatic tissues showed none or very faint PKD1 expression, whereas
all of PDAC tissues showed moderate to high PKD1 expression (Figure 3-1A). Overall,
PKD1 expression was significantly (P < 0.0001) higher in PDAC compared to normal
pancreatic ductal epithelium. PKD1 expression was predominantly expressed all over the
malignant area of the pancreatic cancer tissues. Our results clearly indicate that PKD1
expression effectively differentiated PDAC from healthy controls.
The Mean Composite Score (MCS) was calculated for both normal and pancreatic
cancer tissues, and was obtained by multiplying percentage intensity and percentage of
tissue staining (Figure 3-1B and 3-1C). These results clearly suggest that PKD1 is
overexpressed in pancreatic cancers and might have an oncogenic role in the malignant
transformation of pancreatic cells.
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Figure 3-1. PKD1 is Highly Expressed in Human Pancreatic Cancer Tissues
(A) Immunohistochemistry showing the expression of PKD1 protein in normal and
various stages of pancreatic cancer human tissues. (B) Graph showing the mean
composite scores of PKD1 staining in normal pancreatic tissues and the different stages
of pancreatic cancer. (C) Quantification and depiction of the mean composite score in
overall normal and pancreatic cancer tissues. **p<0.0001.
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We also investigated the expression level of PKD1 in 6 pancreatic cancer cells,
which includes, HPAF-II, Panc-1, Capan-1, MiaPaca, AsPC1 and BxPC3 cells. Except
HPAF-II and BxPC3, which showed less expression of PKD1, most pancreatic cancer
cells had high expression of PKD1 at both protein (immunoblotting and confocal
immunofluorescence, (Figure 3-2A, B) and mRNA levels (PCR) (Figure 3-2C).
PKD1 Contributes to Tumorigenic Characteristics via Glucose Modulation
PKD1 overexpression or activation has been reported to facilitate survival and
proliferation of pancreatic cancer cells [171]. Additionally, PKD1 is involved in trans
differentiation of pancreatic acinar cells to a duct-like, pluripotent progenitor cell type
(ADM, acinar-to- ductal metaplasia), leading to the initiation of pancreatic cancer[172].
Although, studies suggest the oncogenic role of PKD1 in pancreatic cancer, the precise
mechanisms directly influencing the PKD1 induced tumorigenic characteristics are not
elucidated. These studies are essential to develop strategies to control malignant
transformation as well as increased tumor growth in pancreatic cancer. To investigate the
underlying molecular mechanisms, we generated PKD1 overexpressing HPAF-II and
BxPC3 cells (having low PKD1) using transient transfection. The transient transfection
was performed to observe the abrupt molecular changes in the cell on altering the PKD1
expression. We observed an increase in the protein and mRNA levels of PKD1
expression in the both transfected cells, HPAF-II and BxPC3 using immunoblotting and
PCR, respectively (Figure. 3-3A, B). We observed an increase in the percentage of cell
viability on overexpression of PKD1 in both cells, HPAF-II and BxPC3 (Figure 3-3C).
In order to investigate the role of PKD1 on glucose modulation in pancreatic cancer cells,
glucose and lactate assays were performed in PKD1 overexpressing cells, HPAF-II and
BxPC3. We observed significantly (p < 0.05) higher upregulation of glucose
consumption and L-lactate production in PKD1 overexpressing cells as compared to the
control cells having basal levels of PKD1 (Figure. 3-4A, B). Therefore, these results
indicate that PKD1 contributes to altered glucose metabolism of pancreatic cancer cells.
Our results further demonstrated increased migration (Figure. 3-5A, B). and invasive
(Figure. 3-6A, B) potential of HPAF-II and BxPC3 cells with PKD1 overexpression as
compared to the control cells with basal levels of PKD1. We further investigated if the
changes in glucose metabolism alter the enhanced tumorigenic characteristics of the cells
on PKD1 overexpression. Our results demonstrate that the migration (Figure. 3-5A and
3-5B). and invasive potential (Figure. 3-6A, B) of PKD1 overexpressing cells can be
reduced by inducing glucoprivic conditions using 2-deoxyglucose or potentiated by using
lactate (2 mM), an end product of aerobic glycolysis, in the cells. This further suggested
the involvement of glucose accelerated mechanisms acquired by pancreatic cancer cells
on PKD1 overexpression that accompanies enhanced tumorigenesis.
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Figure 3-2. Differential Expression of PKD1 in Pancreatic Cancer Cells
(A) Western blot showing the expression level of PKD1 in different pancreatic cancer
cell lines. HPNE is a normal pancreatic cell line. (B) Real-time PCR depicting the
expression level of PKD1 in a panel of pancreatic cancer cells. (C) Confocal images
depicting the expression level of PKD1 in pancreatic cancer cells. Cells were fixed,
stained and analyzed by confocal microscopy. DAPI was used for nuclear staining.

53

Figure 3-3. Overexpression of PKD1 Increases Cell Proliferation in Pancreatic
Cancer Cells
(A) Pancreatic cancer cells (HPAF-II and BxPC3) were transfected with EGFP control
and EGFP-PKD1 plasmid. Western blot showing the expression of PKD1. (B) Real-time
PCR indicating the expression level of PKD1 after transfection. (C) Cell proliferation
assay depicting the effect of PKD1 on cell viability. *p<0.05.
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Figure 3-4. PKD1 Enhances Glucose Metabolism in Pancreatic Cancer
(A) Lactate and (B) Glucose assays were performed in HPAF-II and BxPC3 cells after
PKD1 transfection. Media from cells was collected after 24 and 48 hours respectively, to
determine glucose uptake levels and lactate production using commercial kits. *p<0.05.

55

Figure 3-5. Glucose Metabolism is Enhanced by PKD1 in Pancreatic Cancer Cells
(A) Boyden chamber migration assay was performed after treatment with L-Lactate
(2µM) and 2-deoxyglucose (2DG, 10µM). The crystal violet stained cells were imaged at
18 h. Magnification of images is 200X. (B) Quantitative depiction of total migratory
cells. n=3; *p<0.05.
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Figure 3-6. PKD1 Accelerates Glucose Metabolism in Pancreatic Cancer Cells
(A) Matrigel invasion assay was conducted in pancreatic cancer cells after L-Lactate
(2µM) and 2-deoxyglucose (2DG, 10µM) treatment. Staining of cells was done using
crystal violet, and after 24 hours, the experiment was terminated and images were taken
at 200X. (B) Representative quantification of the invasive cells. n=3; *p<0.05.
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PKD1 Expression Leads to Increased Expression of Signaling Proteins That Trigger
Enhanced Glucose Metabolism
Alteration of metabolic processes require the interplay between pletoire of
signaling events involving changes in the expression of proteins. Glucose transporter 1 or
GLUT1 is an important protein that facilitates the transport of glucose across the plasma
membranes of cancer cells [173]. Our results demonstrate that PKD1 overexpression in
PanCa cells, HPAF-II and BxPC3, results in an upregulation of protein as well as mRNA
expression of GLUT1. We also observed an increased protein and mRNA expression of
hypoxia-inducible factor or HIF-1 α, which has a role in metabolic switching and
regulates glucose metabolism [174] (Figure. 3-7A, B and (Figure. 3-8A, B). Therefore,
we were interested to understand the underlying molecular mechanisms that may be
involved in metabolic alterations accompanied by PKD1. Since mTOR signaling is
widely reported to regulate HIF‑1α protein synthesis, we particularly investigated mTOR
pathway[175]. mTOR is known as a master regulator of growth and metabolic state of
cells in response to nutrients and extracellular stimuli. Interestingly, our results clearly
demonstrated that PKD1 overexpression enhances the phosphorylation of mTOR
(Figure. 3-7A, B). These results were confirmed when the silencing of endogenous
PKD1 in Panc-1 cells (having high PKD1 expression) inhibited aforementioned events
(Figure. 3-7C). In addition to the phosphorylation of mTOR, endogenous expression of
GLUT-1 and HIF-1 α was observed to be reduced on silencing endogenous PKD1
expression, which suggests that PKD1 induced metabolic changes may be influenced by
mTOR phosphorylation (Figure. 3-7C). We next sought to investigate whether the
hypoxic environment has any effect on PKD1 induced tumorigenic effects. BxPC3 and
HPAF-II cells cultured in a hypoxic environment displayed more cell proliferation
(Figure. 3-9A, B) and high clonogenicity (Figure. 3-10, B) with formation of greater
number of colonies on PKD1 overexpression as compared with cells under normoxic
environment.
PKD1 Increases Glucose Metabolism via mTOR C1 Activation
We set out to analyze whether mTOR phosphorylation regulates the formation of
either mTORC1 or mTORC2. mTORC1 is known to modulate HIF-1 α, which stimulates
glycolysis and glucose uptake. In order to elucidate the possible involvement of
mTORC1, the major downstream effectors of mTORC1 are the ribosomal S6 kinase
(S6K) and the inhibitory eIF4E-binding proteins (4E-BPs). mTORC1 activation
phosphorylates S6K and 4E-BP, which phosphorylates/activates downstream proteins
involved in initiation and elongation [176]. We found that PKD1 overexpression in
PanCa cells results in enhanced phosphorylation of both the effectors of mTORC1,
pS6kinase and 4EBP1. To our expectation, the silencing of endogenous PKD1 inhibited
phosphorylation/activation of both the downstream effectors of mTORC1. In addition to
pS6kinase and 4EBP1 upregulation, an upregulation of p-AKT, a major effector of
mTORC2 was observed on PKD1 overexpression (Figure. 3-11A) that annotated the
activation of both mTORC1 and mTORC2 that belongs to mTOR complex. Since
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Figure 3-7. PKD1 Modulates the Expression of Important Proteins Involved in
Enhanced Cancer Cell Metabolism
(A), (B) Western blot showing the expression level of key proteins associated with
glucose metabolism after overexpressing PKD1, and (C) silencing PKD1.
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Figure 3-8. PKD1 Elevates the Expression of Associated Genes with Glucose
Metabolism
(A), (B) Changes in real time expression of important genes involved in glucose
metabolism by quantitative real-time PCR. Increased level of HIF-1 α and Glut-1
expression was observed in PKD1 expressing cells (HPAF-II and BxPC3 cells). n=3;
*p<0.05.
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Figure 3-9. PKD1 Overexpression Increases Cell Proliferation Under Both
Normoxic and Hypoxic Conditions
Effect of PKD1 on the pancreatic cancer cells was observed in normoxic and hypoxic
environment. The cells were counted and recorded in (A) HPAF-II, and (B) BxPC3 cells.
*p<0.05.
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Figure 3-10. PKD1 Induced Cell Proliferation is Independent of Oxygen Tension
Colony formation assay was performed under normoxic and hypoxic conditions in (A)
HPAF-II and (B) BxPC3 cells. 250 cells were seeded in 12 wells plate. The cells after 7
days were fixed using ice cold methanol, stained and imaged. n=3, *p<0.05.
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Figure 3-11. PKD1 Enhances Glucose Metabolism Through Activation of AKTmTOR Pathway
(A) Western blot to analyze the expression level of important proteins associated with
mTORC1 and mTORC2 pathway. (B) Western blot depicting the expression of p-mTOR
and ps6kinase in presence and absence of rapamycin. (C) Immunoblotting showing the
expression of mTORC1 and mTORC2 after transfection with PKD1 kinase dead domain.
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mTORC1 is rapamycin sensitive, we investigated the effect of PKD1 overexpression in
presence of Rapamycin on the phosphorylation of pS6kinase and mTOR-S2448, major
phosphorylating domain of mTORC1. We observed that Rapamycin treatment prevented
the increase in phosphorylation of both pS6kinase and mTOR-S2448, indicating that
mTORC1 is the main effector of PKD1 (Figure. 3-11B). It is known that the kinase
domain of PKD1 is involved in the activation/phosphorylation of proteins [86].
Therefore, in order to investigate whether the kinase region is responsible for the
increased activity/phosphorylation of mTOR, BxPC3 cells were transfected with the
PKD1 kinase dead domain (PKD1-KD). Immunoblotting demonstrated inhibition in the
phosphorylation of mTOR-S2448 but not mTOR-S2481 (major phosphorylating domain
of mTORC2) in cells transfected with PKD1-KD. The above results inferred two vital
conclusions; PKD1 directly phosphorylates mTOR-S2448 through its kinase domain and
mTORC1 being the downstream effector of PKD1 (Figure. 3-11C). We next asked
whether mTORC1 is involved in PKD1 modulated glucose metabolism. For this, we
investigated the changes in the lactate production and glucose consumption in PKD1
overexpressed cells in presence or absence of Rapamycin. Our results clearly showed that
the PKD1 expressing cells in presence of Rapamycin failed to increase lactate production
and glucose consumption (Figure. 3-12A). These effects were confirmed by using
siRNA mediated knockdown of Raptor or Rictor, which are the determinants of the
activation of mTORC1 and mTORC2, respectively [72], in addition to PKD1
overexpression in cells. siRNA directed to Raptor but not Rictor, inhibited the lactate
production and glucose consumption triggered by PKD1. No noticeable changes were
observed on silencing rictor. As raptor is an important component of mTORC1 complex
[72], these results indicated an obvious role of mTORC1 pathway in the aberrant
metabolism induced by PKD1 (Figure. 3-12B).
PKD1 Expression Leads to Gemcitabine Resistance and Its Inhibition Sensitizes
Gemcitabine
High glucose accelerates cell proliferation in pancreatic cancer cells and imparts
chemoresistance. Metabolic dysregulation is one of the most common and recognizable
features of cancer. This facilitates the change in response to substrate availability due to
metabolic demands of cell during proliferation, growth and cell survival [11].
Cancer/proliferating cells alter their ability to metabolize biomolecules to meet increased
energy demands. It has been recognized that cancer cells increase glycolytic lactate
production independent of oxygen availability [177].
In addition to studies related to the role of PKD1 in glucose metabolism, we were
interested to investigate its effect on anticancer therapy. Therefore, we wanted to
investigate the effect of aberrant glucose metabolism on the outcome of drug treatment in
PanCa cells and investigate whether response to drugs can be affected by excessive
glucose metabolism. Therefore, upon treatment of cells with lactate (2µM, 48 hours), we
observed an increase in the viability of the cells and resistance to gemcitabine treatment
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Figure 3-12. Glucose Metabolism is Accelerated by PKD1 Through mTOR
Pathway
(A) Lactate and glucose assay in presence and absence of rapamycin (B) Lactate and
glucose assays were performed after raptor and rictor silencing, which are essential
components of mTORC1 and mTORC2 complex, respectively.
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(Figure. 3-13A). Treatment of cells with 2DG resulted in decreased viability and restored
gemcitabine sensitivity (Figure.3-13B). Additionally, an induction of apoptosis by
gemcitabine was observed in presence of 2DG as depicted by activation
of apoptotic protein, Bax, cleavage of PARP and inhibition of antiapoptotic Bcl-2
(Figure.3-13C). In order to investigate the role of PKD1 in chemoresistance, we
analyzed the effect of PKD1 overexpression on cell viability and gemcitabine resistance,
we observed an enhanced cell viability on PKD1 overexpression (Figure.3-13Di) and
resistance to gemcitabine (Figure.3-13Dii). Suppression of PKD1, using siRNA
mediated knockdown, reduced the cell viability as well as gemcitabine (Figure.3-13Ei,
ii) in the proliferation. These outcomes indicate that expression of PKD1 in pancreatic
cancer cells result in chemoresistance, which attributes to the deregulated glucose
metabolism and its suppression sensitizes gemcitabine in pancreatic cancer cells.
Discussion
Excessive glucose metabolism is a significant characteristic feature of cancer.
Pancreatic cancer cells require large amounts of glucose for their survival. It leads to the
fast growth and proliferation of the cancer cells. Many signaling molecules are reported
to play an essential role in the aberrant metabolic processes, but further studies are still
required to develop effective treatment strategies targeting glucose metabolism [157].
Several reports indicate an oncogenic role of the PKD1 protein in pancreatic cancer, but
the mechanisms involved have not been sufficiently defined [87, 164]. This study
demonstrates the role of PKD1 in enhancing glucose metabolism of pancreatic cancer
cells and defines the underlying molecular mechanisms. Additionally, this study
determines an important role of PKD1 in pancreatic cancer chemoresistance.
In the present study, we demonstrate that PKD1 is highly expressed in human
Pancreatic ductal adenocarcinoma (PDAC) as compared with less or no expression in
normal pancreatic tissues. This is a first study to our knowledge, which presents the
expression profile of PKD1 in human PDAC. The oncogenic role of PKD1 in PanCa is
growing interest among the scientific community and several reports suggest its role in
pancreatic tumorigenesis [87, 89, 164]. Herein, we demonstrate a functional role of
PKD1 in maintaining glucose metabolism of PanCa cells and illustrate signaling
mechanisms that regulate the underlying molecular processes accompanying altered
glucose metabolism. The results in this study demonstrate that PKD1 overexpression
leads to enhanced lactate production and glucose consumption while PKD1 knockdown
may lead to reduction in both. The results were similar with the supplementation of cells
with lactate that potentiates the migration and invasion of PanCa cells. While
supplementation of cells with 2-DG, a glucose analog that inhibits glycolysis [28, 38],
restores the PKD1 induced tumorigenic effects. These data suggest that PKD1 promotes
tumorigenesis by modulating glucose metabolism and warrants further investigation for
underling mechanisms. As PKD1 was also observed to effect the expression hypoxiainducible factor 1 (HIF-1), further investigations revealed hypoxic environment being
conducive to increased effects on cell growth, as depicted by ability of cells to colonize
and warranted further investigation.
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Figure 3-13. PKD1 Expression Leads to Chemoresistance and its Inhibition
Sensitizes Gemcitabine
(A) Cell proliferation assay in pancreatic cancer cells in presence of L-Lactate and
gemcitabine (B) Cell viability experiment in pancreatic cancer cells was performed in
presence of 2-DG and gemcitabine (C) Western blot showing the expression of apoptotic
proteins after treatment with 2DG and gemcitabine (D), (E) MTT assay in PKD1
expressing and null cells was conducted in presence and absence of gemcitabine.
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mTOR is the conserved serine/threonine kinase that regulates the proliferation and
metabolism in cells. mTOR exists in two distinct complexes with different protein
components and downstream substrates; mTOR complex C1 and C2 [178]. mTORC1
stimulates HIF-1α regulating various enzymes for glucose metabolism, including glucose
transporters [179]. This study demonstrates that PKD1 phosphorylates/activates
mTORC1 in pancreatic cancer cells as was depicted by the increased
activation/phosphorylation of its main effectors, pS6K and 4EBP1 on PKD1
overexpression. However, the kinase dead mutant of PKD1 did not enhance the
phosphorylation/activation of the major phosphorylating domain of mTORC1, mTORS2448. The detection of reduction in the phosphorylation of mTOR-S2448 in cells
expressing kinase mutant of PKD1 can be explained well with the fact of a new
phosphorylated protein not being produced while the accumulated protein being degraded
with time (Fig. 6C). These results indicate that PKD1 activity was necessary for
mTORC1 activation. mTORC1 inactivation by rapamycin is critical for glucose
metabolism [180, 181]. Rapamycin binds to the FK506-binding protein of 12 kDa
(FKBP12) and inhibits the activity of mTORC1 [182]. Our findings further demonstrate
that mTORC1 activation by PKD1 regulates metabolic alterations in pancreatic cancer
cells. These results were quite convincing as the treatment of rapamycin inhibited PKD1
accelerated lactate production as well as glucose consumption in cancer cells.
Additionally, the significance of mTORC1 activation in PKD1 induced metabolic
alterations was established on silencing raptor, the main determinants of the activation of
mTORC1, which inhibited the metabolic changes associated with PKD1. Since no
significant alterations were detected on silencing rictor, confirms the association of
mTORC1 with PKD1 induced metabolic alterations. In other words, it can be stated that
the promotion of glycolysis by PKD1 can be regulated by mTORC1 suppression and this
concept can be utilized to develop novel therapeutic strategies.
Another major finding in this study demonstrates the role of PKD1 in
chemoresistance. The results presented in this study suggesting that PKD1 induces
chemoresistance due to aberrant glucose metabolism are significant. Additionally, we
demonstrate that altered glucose metabolism interferes with the sensitivity of the drug
and its outcomes in PanCa cells. Our data suggests that PanCa cells become resistant to
chemotherapeutic drugs in presence of enhanced glucose, which can be overcome by
depleting the glycolysis. An induction of apoptosis by gemcitabine was achieved in
presence of 2DG as depicted by activation of apoptotic protein, Bax, cleavage of PARP
and inhibition of anti-apoptotic Bcl-2. Our observations identify that modulation of
PKD1 expression can turn the PanCa cells sensitive. This was indicated by using siRNA
mediated knockdown of PKD1 that rendered these cells sensitive to gemcitabine
treatment.
In conclusion, we present the expression profile of PKD1 in human PanCa tissues
and demonstrate that PKD1 is aberrantly expressed in PanCa as compared with normal
pancreatic tissues. Our results suggest a novel role of PKD1 contributing to aberrant
glucose metabolism in pancreatic cancer cells which accelerates PanCa tumorigenesis
and chemoresistance. These interesting findings strongly indicate that PKD1 can be
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explored as a novel therapeutic target and as a biomarker, inhibition of which can reduce
pancreatic cancer progression and metastasis. The association of PKD1-induced mTOR
pathway can be used as a therapeutic strategy for the emergence of new drugs to target
pancreatic cancer. Moreover, as suggested by our results, PKD1 has a role in
chemoresistance owing to dysregulated glucose metabolism in pancreatic cancer.
Therefore, it can further be exploited to increase the survival rate of pancreatic cancer
patients. The overall mechanism of PKD1-induced metabolic reprogramming through
mTOR is depicted in Figure 3-14.
Further, we wanted to identify a drug which could inhibit the elevated glucose
metabolism in pancreatic cancer with less toxicity to the normal cells. Also, it was
essential to determine the therapeutic potential of the drug in terms of inhibition of the
oncogenic protein molecules identified earlier in our studies (MUC13 and PKD1).
Therefore, we selected a plant-derived compound, steviol for our further studies, which
could both restore glucose metabolism and act as a chemo-preventive agent.
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Figure 3-14. Proposed Mechanism Describing the Role of PKD1 in Impaired
Glucose Metabolism in Pancreatic Cancer
PKD1 induces metabolic reprogramming in pancreatic cancer through mTOR pathway.
This mechanism results in increased glucose metabolism, proliferation and
chemoresistance of pancreatic cancer cells.
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CHAPTER 4. STEVIOL: A NATURAL SWEETENER, INHIBITS
PANCREATIC CANCER PROGRESSION THROUGH SUPPRESSION OF
ABERRANT GLUCOSE METABOLISM
Introduction
Pancreatic cancer (PanCa) is one of the deadliest malignancies, and accounts for
many mortalities worldwide [1]. The lack of early detection, chemoresistance and
metastatic profile contributes to the highly aggressive behavior of this disease [1].
Therefore, it is essential to understand the underlying mechanisms of this disease, which
can prolong the survival rate of the affected patients.
Stevia is a plant product and is obtained from Stevia rebaudiana. It has a low
calorie content, but is almost 300 times sweeter than the normal cane sugar. The
metabolism of steviol begins in the human gut when stevioside (precursor of steviol) is
converted to steviol 16,17α-epoxide, and then to steviol through the action of bacteria
present in the gut [130]. After the completion of the metabolic process, it is relatively
easier for steviol to get absorbed in the blood following oral administration. New studies
have indicated that stevioside is very effective in reducing high glucose levels and
inflammation. Reports also suggest that it has potent anti-cancer properties in different
cancers, demonstrating its therapeutic properties [126-129]. Stevioside has been found to
be a potent compound, as it can decrease the glucose levels in blood in humans [131] and,
also in rats [132]. These indicate the safety, low toxicity, and valuable properties of
steviol on glucose metabolism. Nevertheless, the role of steviol in the regulation of
glucose metabolism has not been clearly elucidated.
Aberrations in the translation process is a unique feature associated with cancer
progression. A variety of key tumor suppressor and oncogenic factors are involved in this
process and drive this mechanism [79]. The initiation step of translation process is the
most prominent and tightly co-ordinated phase. Deregulation of some of the important
pathways- PI3K/AKT/mTOR are mainly responsible for the abnormal functioning of the
translation initiation apparatus [183, 184]. The eukaryotic initiation factors (eIFs) are the
key proteins which are strongly associated with the translation complex. So far, 6 eIFs
have been reported, namely, eIFs1-6. Alterations in their regular function leads to
emergence of an oncogenic behavior [79, 184]. Therefore, targeting these molecules is
essential for cancer treatment, paving the way for development of new therapeutic drugs.
The cancer cells undergo dysregulated glucose metabolism in order to sustain
growth and proliferation rapidly. This also involves the upregulation of tumor promoting
genes [185]. In comparison to the quiescent cells, the cancerous cells do not use oxidative
phosphorylation, but rather utilize the aerobic glycolysis mechanism [186]. This
mechanism is also called the Warburg effect and is extensively researched. During this
process, large amount of energy is released in the form of ATP as glucose uptake is high
in comparison to the normal cells, which in turn also secretes abundant amount of lactate.
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This also creates an acidic microenvironment [187]. In addition, the chemo-resistant
tumor cells need more glucose for their survival and continuous growth. Hence, it is
mandatory to target the glucose metabolic networks and increase sensitivity of the drug
resistant cells, in order to enhance the efficiency of the drugs used for chemotherapy, as a
result also increasing the lifespan of the suffering patients due to pancreatic cancer [188].
As steviol modulated glucose metabolism in our current study, we believe that
this might be one of the reasons for its mode of action in influencing translation
apparatus. This is the first study on steviol describing the underlying mechanism through
inhibition of translation initiation in pancreatic cancer. In addition, we also observed
inhibitory role of steviol as it suppressed the expression of both MUC13 and PKD1
(proteins in association with glucose metabolism), in our studies. Overall, this research
work identifies the potential role of steviol in inhibiting pancreatic cancer through various
mechanisms, and suggests that it can be a promising drug candidate for therapeutic
intervention either alone or with combinatorial strategies.
Materials and Methods
Cell Culture
Pancreatic cancer cells (HPAF-II and AsPC1) were used for this study. These
cells were maintained in DMEM/F12 or RPMI media, respectively, containing 10% fetal
bovine serum. The incubation conditions used were 37ºC temperature with 5% CO2..
Western Blotting
Cell lysates were prepared and western blotting was performed [11]. Samples
were loaded on a gel (4-20%), ran for 90 minutes. Thereafter, the gel was transferred onto
a PVDF membrane for 70 minutes duration. Further, the membranes were blocked in 5%
milk for 1 hour, on a slow shaker, followed by incubation with the respective primary
antibodies overnight at 4oC. The secondary antibodies were added for 1 hour next day,
after washing the membranes with 1X TBST buffer, and the blots were developed with
an ECL solution on a UVP machine.
Antibodies
Primary antibodies from Cell Signaling Technology were used to analyze the
expression of important proteins, Bcl-2 (catalog # 4223S), Bax (catalog # 2772S), Bcl-xl
(catalog # 2764S), eIF4e (catalog # 9742S), peIF4e (catalog # 9741S), 4EBP1 (catalog #
9452S), p4EBP1 (catalog # 2855S), mTOR (catalog # 4517S), p-mTOR (catalog #
5536S), eIF4B (catalog # 3592S), peIF4B (catalog # 3591S), eIF4G (catalog # 2498S),
peIF4G (catalog # 2441S). Cleaved PARP (sc-8007) and Cyclin D1 (sc-753)
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antibodies were obtained from Santa Cruz Biotechnology. Beta-actin antibody was
obtained from Sigma (catalog # A2228). The secondary antibodies from Promega were
used for rabbit (catalog # 4011), and mouse (catalog # 4021) conjugated with horseradish
peroxidase.
Proliferation Assay
MTT assay was performed on pancreatic cancer cells to access the cell
proliferation properties. This assay was terminated after 48 hrs by adding 20 µl of MTT
reagent to the cells. After 2 hours of incubation, 100 µl of DMSO was added to the cells,
and the plate was kept on shaker for 10 minutes. Further, the absorbance was recorded at
570 nm, the viability of cells was determined and quantified.
Migration Assay
Cell migration assay was performed using Boyden chamber [169, 170]. 5*10^4
cells were seeded per well in a 96 well plate on the upper chamber with media devoid of
serum. On the other hand, the lower chamber contained 250µl of media with serum. The
cells were treated with steviol at different concentrations and further incubated for 18
hours. The cells were fixed with 4% PFA, followed by staining using crystal violet
reagent for about 1 hour. Thereafter, the plate was washed using tap water. The images
were captured after the cells were dried.
Invasion Assay
The cell invasion assay was conducted in pancreatic cancer cells using Matrigel
Invasion Chambers obtained from BD Biosciences [149]. The chambers were rehydrated
for 2 hours in media without any serum content. Further, the cells were seeded
(25*10^4/chamber) in 500 µl of serum-free media. Next day, the cells were treated with
steviol at various concentrations in the chamber followed by incubation of 24 hours.
Fixation of cells was done using cold methanol and staining was performed using crystal
violet. Then, the washing of cells was done, and images were captured after 24 hours.
Real-Time xCELLigence Assays
To analyze the effect of steviol on pancreatic cancer cells, real-time proliferation
and migration assays were conducted on xCELLigence instrument. Cells were seeded on
the respective plates and were incubated in a 37ºC incubator with 5% CO2 condition. The
experiment was terminated at the indicated time points and the results were analyzed.
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Clonogenic Assay
Cells were seeded (250) in 12 wells plate, and were incubated for 3-4 days to
form colonies. The treatment was done immediately as soon as colonies started to appear.
The experiment was terminated following 15 days after washing cells with cold PBS,
fixed with cold methanol, and cells were stained with crystal violet. Further, the plates
were left for drying and then the images were captured. The number of colonies were
recorded and compared.
Cell Cycle Studies
This assay was performed through the Telford method. The cells were seeded
(0.5*10^6) in a 6-wells plate, and was incubated overnight. Pancreatic cancer cells were
treated with steviol for 12 hours and 24 hours. The cells were trypsinized, washed with
cold PBS and fixed with 70% ethanol. Further, the cells were incubated at 4ºC for 1 hour
and later stained with propidium iodide for about 4 hours in the dark (at 4ºC). The
analysis was done in an FL2 channel, using cell cycle instrument, and ModFit software.
Lactate Assay/ Glucose Assay
Both assays were conducted as described in our previous publication [11]. The
assays were conducted following the instructions mentioned in the kits (Cayman
Chemicals). Thereafter, the absorbance readings were recorded, followed by plotting of
the respective graphs based on the calculations.
Statistical Analysis
The statistical analysis for this manuscript was conducted by Student’s t test. The
p-values < 0.05 were accounted as statistically significant.
Results
Steviol Effectively Suppressed MUC13 and PKD1 Proteins
We wanted to first investigate the therapeutic potential of steviol with respect to
the proteins identified to be involved in dysregulated glucose metabolism, in our previous
chapters. Therefore, we accessed the inhibition of the oncogenic proteins, MUC13 and
PKD1, with steviol treatment. The concentration of steviol selected was based on some
preliminary studies in our lab. It was observed that the expression levels of both MUC13
and PKD1 proteins were significantly decreased in a dose-dependent manner (Figure
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4-1A, B). This exciting data indicates that steviol, as a drug has a lot of therapeutic
potential as it can significantly inhibit these upregulated oncogenic molecules, and
therefore should be explored further to extend the survival chances of pancreatic cancer
patients.
Steviol Inhibits Cell Proliferation and Colony Formation of PDAC Cells
In order to investigate the anti-tumorigenic properties of steviol, functional assays
were performed in pancreatic cancer cells. Steviol treatment showed significant inhibition
of cell proliferation in a dose-dependent manner. It demonstrated an IC50 of 10mM
concentration. Similar trend was observed in both HPAF-II and AsPC1 cell lines (Figure
4-2A).
Also, the colony forming abilities of pancreatic cancer cells (AsPC1 and HPAF-II
cells) were remarkably suppressed by steviol as compared to the untreated cells (Figure
4- 2B).
Steviol Suppresses Cell Migration and Cell Invasion Capabilities of Pancreatic
Cancer Cells
It was interesting to evaluate the functional characteristics of steviol on PDAC cells.
For this, pancreatic cancer cells were treated with steviol at various concentrations and it
was observed that steviol efficiently inhibited the cell migration (Figure 4-3A) and cell
invasion abilities (Figure 4-3B), in a concentration-dependent manner. This indicated the
anti-cancer properties of steviol in pancreatic cancer. Also, the suppression of
proliferation and migration in HPAF-II cells was evaluated by xCELLigence assay after
treatment with steviol. This also demonstrated that steviol was very effective in
substantially reducing the proliferative abilities and migratory potential of pancreatic
cancer cells in a dose-dependent way (Figure 4-4).
Steviol Suppresses Translation Initiation of Pancreatic Cancer
Disruption in the translation initiation machinery directly relates to
carcinogenesis. Various oncogenic molecules and tumor suppressors play a major role in
this pathway[79]. Therefore, it was imperative to understand the mechanism of action of
steviol with regard to this signaling pathway. The expression of proteins associated with
translation was analyzed, after treatment of pancreatic cancer cells with steviol at
different time points The translation machinery was significantly suppressed as depicted
by the immunoblotting assay (Figure 4-5A, B). The most important associated proteins
were significantly downregulated with treatment of steviol such as peIF4E, peIF4B,
peIF4G, p4EBP1, and p-mTOR. These molecules are required for the proper functioning
of the translation initiation process. Steviol treatment clearly inhibited the expression of
these essential proteins, which in turn hampered the formation of new proteins. It has
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Figure 4-1. Steviol Inhibits the Expression of MUC13 and PKD1 Proteins
(A) HPAF-II cells (having high MUC13 expression) were subjected to steviol treatment
at the indicated concentrations for 24 hours. Whole cell lysates were prepared, and
immunoblotting was done to determine the expression of MUC13 protein. (B) Similarly,
AsPC1 cells, which are PKD1 expressing cells, were treated with steviol under similar
conditions. The cellular lysates were made and used for western blotting to analyze the
PKD1 expression after steviol treatment.
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Figure 4-2. Steviol Inhibits Cell Proliferation and Clonogenic Potential of
Pancreatic Cancer Cells
(A) Pancreatic cancer cells were treated with different concentrations of steviol (0, 1, 5,
10 and 15mM), and incubated for 48 hours. Cell proliferation assay was terminated after
addition of MTT reagent and recording the absorbance in HPAF-II and AsPC1 cells. (B).
Colony formation assay was performed on pancreatic cancer cells. The cells were seeded
and after 4 days, treatment with steviol was done at different concentrations (0, 1, 2 and
4mM), and incubated for another 10 days. n=3; *p<0.05.
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Figure 4-3. Steviol Inhibits Cell Migration and Cell Invasion in Pancreatic
Cancer
(A) Boyden chamber migration assay was conducted on HPAF-II and AsPC1 cells. The
cells were treated with 0, 1, 5 and 10 mM concentrations for 18 hours. Then the cells
were fixed with 4% paraformaldehyde, stained with crystal violet and left for drying.
Further, the images were captured (B) Matrigel invasion assay was performed on
pancreatic cancer cells. The cells were treated with steviol at indicated concentrations for
24 hours. Thereafter, the cells were washed with PBS, fixed with methanol and stained
using crystal violet. Upon drying, images were taken.
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Figure 4-4. Steviol Causes Reduction in Cell Proliferation and Cell Migration in
HPAF-II Cells
Pancreatic cancer cells (HPAF-II) were seeded and treated with different concentrations
of steviol (0, 1, 5, 10 and 15mM). The cells were subjected to the xCELLigence
instrument and cell proliferation and cell migration assay (0, 1, 5, 10mM of steviol) were
conducted on the E-plate and CIM plates respectively.
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Figure 4-5. Steviol Impedes Translation Initiation
Cells were treated with steviol at different time points (0, 3, 6 and 9 hours), and whole
cell lysates were prepared. Western blotting was performed to analyze the expression
level of proteins associated with translation initiation in (A) HPAF-II, and (B) AsPC1
cells. The numbers above the blots represent the relative band intensity after normalizing
with β-actin (housekeeping gene).
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been documented that activation of eIF4E increases the key tumorigenic mRNAs
translation in order to enhance oncogenic characteristics [189]. Steviol effectively
decreased the phosphorylation status of this protein, in turn reducing the tumorigenic
activity and delay in the translation process.
Steviol Decreases Glucose Uptake and Lactate Secretion in PDAC Cells
Cancer cells consume more glucose, which is metabolized by the glycolysis
pathway, and lactate is the end product of glucose metabolism. Therefore, we
investigated if steviol could lower the lactate production in PDAC cells. Our findings
indicated decreased lactate secretion in both pancreatic cancer cells (Figure 4-6A).
The tumor cells undergo altered metabolism to support and sustain their
upregulated growth and proliferative capabilities. Studies have reported about the potent
anti-glycemic activity of Steviol precursor in rats and humans [131, 132]. However, its
effect on the regulation of glucose metabolism in cancer cells has not been investigated.
Therefore, we investigated its effect on glucose uptake/total glucose levels in pancreatic
cancer cells Our results suggested that Steviol treatment reduced glucose consumption in
pancreatic cancer cells (HPAF-II and AsPC1 cells) as compared to untreated cells
(Figure 4-6B). These outcomes clearly suggest this compound having strong potential to
suppress altered glucose metabolism in PDAC.
Steviol Induces Apoptosis in Pancreatic Cancer Cells
Apoptosis, commonly referred to as programmed cell death is a characteristic
phenomenon of normal cells [190]. In abnormal conditions, the cells escape this process,
which leads to tumorigenic condition. Several proteins are associated with the apoptotic
pathway. Bax is one of the pro-apoptotic proteins crucially involved in this pathway.
Also, other proteins such as Bcl-2, PARP and Bcl-xL are the significant anti-apoptotic
proteins regulating these processes [191].
It was interesting to evaluate whether steviol has any role in apoptosis. Therefore,
protein expression of apoptotic proteins was examined in pancreatic cancer cells after
treatment with steviol in a time-dependent manner (0, 3, 6 and 9 hours) through
immunoblotting. It was observed that the expression of Bax protein (pro-apoptotic) was
upregulated in both HPAF-II and AsPC1 cell lines. Also, the expression level of
important apoptosis-related proteins: Bcl-2 and Bcl-xL (anti-apoptotic proteins)
decreased significantly in a dose-dependent manner. In addition, increased PARP
cleavage (marker for early apoptosis) was observed after treatment with steviol. These
results collectively indicated that steviol enhances apoptosis in pancreatic cancer as
evident by the increased Bax/Bcl-2 ratio (Figure 4-7A, B).
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Figure 4-6. Steviol Inhibits Lactate Secretion and Glucose Uptake
Lactate and glucose assays were performed using commercially available kits in
pancreatic cancer cells. Steviol treatment resulted in reduced lactate production and
decreased glucose consumption in (A) HPAF-II, and (B) AsPC1 cells. n=2; *p<0.05.
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Figure 4-7. Steviol Inhibits Apoptosis in Pancreatic Cancer Cells
Pancreatic cancer cells were treated with steviol at different time points (0, 3, 6 and 9
hours), and western blotting was conducted after preparation of cell lysates. The
expression level of important proteins associated with apoptotic pathway was evaluated
in (A) HPAF-II, and (B) AsPC1 cells. Quantification of blots with respect to the loading
control (β-actin) was done as depicted by the numbers above the bands.
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Steviol Treatment Results in G1 Cell Phase Arrest and Also Regulates the Proteins
Involved
In general, many drugs act by inducing cell cycle arrest of cancer cells. Therefore,
to investigate the effect of steviol on G1 phase arrest on pancreatic cancer cells in a timedependent manner (0, 12 and 24 hours), cell cycle experiment was performed. It was
observed that steviol induced G1 arrest as depicted through the histogram graphs. The
quantitative G1 population with respect to time is represented in HPAF-II and AsPC1
cells (Figure 4-8A, D).
In order to understand the underlying mechanism of the G1 phase arrest, the
regulatory proteins which are associated with the G1 stage of cell cycle were evaluated to
determine if steviol induced any inhibitory effects on them. Interestingly, the
immunoblotting results demonstrated that the inhibitory proteins associated with cell
cycle, mainly, p18 and p21 were significantly increased upon steviol treatment. On the
other hand, Cyclin D1, which is critically involved in the progression of cell cycle [192],
was remarkably downregulated in presence of steviol in comparison to the normal
(untreated) cells. These observations suggest that steviol effectively modulates the
important cell cycle associated proteins (Figure 4-9A, B).
Discussion
Pancreatic cancer is the most dreadful disease among cancers across the globe,
with higher rates of cancer deaths in USA [1]. In this regard, there is an urgent need to
reduce the death rates and develop fruitful therapeutic options to counteract this disease.
A number of natural compounds with low toxicity profile have been investigated for
cancer in recent years. Steviol is a natural sweetener which has a number of beneficial
properties. As it is derived from a plant, it has low toxicity and thus is safe for use.
Studies have suggested its role as an anti-diabetic and anti-inflammatory compound.
Steviol has also been reported as an anti-cancer agent in different cancers [193, 194]. But
in pancreatic cancer, its effect has not been well established yet. Therefore, this is the first
study investigating the anti-tumorigenic potential of this plant product in pancreatic
cancer.
Steviol inhibited the expression of oncogenic molecular determinants (MUC13
and PKD1), which also prompted us to investigate its role in deregulated glucose
metabolism and also its anti-cancer effects in pancreatic cancer cells. In this research, it
was elucidated that steviol suppresses pancreatic cancer proliferation and growth in two
cell line model systems (HPAF-II and AsPC1). This compound also demonstrated its
strong potential with respect to inhibition of the migration and invasion properties of the
pancreatic cancer cells which was observed through the boyden chamber migration assay,
and Matrigel invasion assay. The real-time xCELLigence assay also illustrated similar
results and thus confirmed our findings.
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Figure 4-8. Steviol Treatment Leads to G1 Arrest
Pancreatic cancer cells were seeded and treated with steviol at different time points (0, 12
and 24 hours). Cell cycle experiment was conducted to determine the effect of steviol on
G1 cell cycle arrest in (A), (B) HPAF-II, and (C), (D) AsPC1 cells.
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Figure 4-9. Steviol Modulates the Key Proteins Involved in G1 Cell Phase Arrest
Pancreatic cancer cells were treated with steviol (10 mM) at different time points (0, 3, 6
and 9 hours). Whole cell lysates were prepared and subjected to western blotting. The
expression level of important cell cycle proteins (p18, p21 and Cyclin D1) were evaluated
in (A) HPAF-II, and (B) AsPC1 cells. The numbers over the blots represent the relative
quantification of band intensities with the internal control (β-actin).
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As steviol is a plant product, it is expected to have multiple targets in oncogenic
signaling pathways. As we observed increased expression of p4EBP1 protein in the cells
treated with steviol, we wanted to investigate the changes in expression level of the
proteins involved in the translation initiation apparatus. The key proteins associated with
the translation machinery was observed to be downregulated in presence of steviol as
indicated by our results. These proteins included: peIF4E, peIF4B, peIF4G, and p-mTOR,
which are strongly associated with the translation-initiation process in eukaryotic cells.
This in turn suggested that the activation of these key players in the process was
disrupted by steviol treatment, further leading to inhibition of the translation mechanism
itself. These findings are observed for the first time, which makes steviol a promising
candidate for future studies.
In addition, our studies indicate that steviol inhibits apoptosis in pancreatic cancer
cells, as suggested by the reduction in the expression level of apoptotic proteins such as
Bcl-2 and PARP. Also, steviol leads to G1 cell cycle arrest, as observed through a rise in
G1 phase population in a time-dependent manner. Our findings also indicate that steviol
is very effective in regulating the prominent cell cycle associated proteins, namely p18,
p21, as well as Cyclin D1 protein levels.
Altered glucose metabolism is an essential feature of pancreatic cancer.
Therefore, it was imperative to investigate whether steviol can inhibit the aberrant
metabolism. Our research demonstrated that steviol treatment with increasing
concentrations, led to significant decrease in the glucose consumption in pancreatic
cancer. Furthermore, the lactate secretion was also reduced when cells were treated with
steviol in a concentration-dependent manner. These findings delineate the strong
potential of steviol in overcoming the metabolic shift in pancreatic cancer.
Our results demonstrate that steviol has a significant role in modulating glucose
metabolism, that might be involved in regulating the translation machinery through
mTOR/AKT/PI3K altered mechanisms. We speculate that the alterations in glucose
metabolism by steviol is the main factor which results in the suppression of translation
machinery mechanism.
In conclusion, steviol, with regard to its beneficial effects of being minimally
toxic and safe, can be considered as an effective anti-cancer agent, and be used in
combination with other chemotherapeutic drugs to enhance the survival rate of pancreatic
cancer patients. In the near future, it can be considered as an ideal candidate for more
advanced research in this direction to develop promising therapeutic strategies to
overcome this deadly disease.
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CHAPTER 5.

CONCLUSION AND FUTURE DIRECTIONS

Pancreatic cancer cells demonstrate deregulated glucose metabolism and
constitutive activation of several oncogenic signaling pathways leading to aggressive
growth and metastatic phenotypes. These cells reshape their glucose metabolism in order
to satiate the energy requirement in growing tumors and progression of metastasis. These
metabolic adaptions promote the aerobic glycolytic events instead of oxidative
phosphorylation resulting in the accumulation of lactate, subsequently altering the
conditions in tissue microenvironment and driving it towards acidic milieu. Collectively,
these developments trigger the excessive glucose metabolism in pancreatic tumors by
facilitating cell proliferation in tumors. High glucose metabolism is a characteristic
feature of pancreatic cancer and it fulfils the energy requirements of cancer cells. Due to
the occurrence of these chronological events, the survival rate of the patients suffering
from pancreatic cancer worsens. Studies have suggested that surgical removal of tumors
from pancreatic cancer patients restored glucose metabolism [195]. Clinical data from
another research signifies that diabetes mellitus in pancreatic cancer occurs as a result of
the cancer itself [196].
However, there are only limited resources available about upstream key signaling
molecules that regulate the downstream effector molecules which promote the activation
of deregulated glucose metabolism. We believed that the identification of novel proteins
in connection with aberrant glucose metabolism and therapeutic targeting would provide
new dimensional approach for the treatment of pancreatic cancer patients with
dysregulated glucose metabolism. MUC13 protein has been extensively studied in our
lab, and we have identified its predominant role in pancreatic cancer development and
progression. However, its role in altered metabolism had never been elucidated, which
made it a probable candidate for our investigation. Also, Protein Kinase D molecules
have been identified to be associated with glucose uptake/consumption in cardiac
hypertrophy [137], but their role in cancer remains unidentified. Protein Kinase D1
(PKD1) is a kinase protein reported to be involved in hypoxic metabolism in other
cancers [138], and has also been investigated extensively by our group. However, its role
in pancreatic cancer and the associated mechanisms have not been very well investigated.
Therefore, we were interested in investigating its association with elevated glucose
metabolism which might further contribute to tumorigenesis and metabolic alterations.
With this note in chapter 2, we first evaluated the preeminent role of MUC13 as
disruptor of glucose metabolism in pancreatic cancer cells. The results demonstrated that
expression of MUC13 led to the activation/nuclear translocation of NFҡB/p65 and
phosphorylation of IҡB. This resulted in the upregulation of downstream proteins (Glut1, c-Myc, and Bcl-2) those were involved in homeostasis of glucose metabolism. Our
data demonstrate physical interaction of MUC13 with glucose receptor Glut-1. This
interaction stimulated the downstream signaling leading to the promotion of enhanced
intracellular glucose uptake. Our findings indicate that altered expressions of MUC13
governs the uptake of glucose, lactate accumulations and expression of metastatic genes.
In addition, a NFκB inhibitor (sulfasalazine) interrupted the molecular interaction of
88

Glut-1 and MUC13, that subsequently interfered with MUC13 induced altered glucose
metabolism. Further, pancreatic ductal adenocarcinoma (PDAC) patient tissue samples
displayed a decisive correlation and confirmed the association of MUC13 and Glut-1.
These results deciphered mechanistic insight of MUC13 and its involvement in rewiring
glucose metabolism that promoted the invasiveness of pancreatic cancer.
Concisely, we elucidated the functional role of MUC13 in rewiring of a discrete
glucose metabolic network that initiates advantageous tumor microenvironment resulting
in the activation of oncogenic signaling in pancreatic cancer cells that favored the
metastasis. The inhibition of MUC13 by therapeutic agents specifically restrained the
pancreatic tumor growth and subsequently interfered with the glycolytic influx. The
dependence of pancreatic tumor growth and metastasis on MUC13-Glut-1 mediated
glucose metabolism can be harnessed as molecular target for the therapeutic
developments. Altogether, our study offered a propitious target for therapeutic
interventions by reinstating the glucose metabolism in pancreatic cancer patients, thus
being a promising strategy for extending the survival span in patients. Altogether, we
conclusively demonstrated the role of MUC13 as a pro-regulator of dysregulated glucose
metabolism and identified it as a clinical key molecule in pancreatic cancer patients with
aberrant glucose metabolism. The discovery of this novel insight will encourage the
development of newfangled therapeutic strategies for the pancreatic cancer patients
suffering from dysregulated glucose metabolism.
Further, in search of associated proteins which are involved in dysregulated
glucose metabolism in pancreatic cancer, we explored other possible candidates. In this
view from chapter 3, we investigated the probable protein, Protein Kinase D1 (PKD1),
with key functional role in rewiring of the glucose metabolism. Previously, few studies
on PKD1 have inferred its role as an oncogenic protein in pancreatic cancer, but it’s role
in regulating glucose metabolism has not been completely elucidated. Therefore, in
Chapter 3, we have shown expression profile of PKD1 in PDAC tissues and cells. The
profiling results clearly indicates that PKD1 is overexpressed in pancreatic cancer tissues
and cells compared to normal human tissues and cells. Our results also demonstrated that
overexpression of PKD1 led to increased proliferation, invasion and migration of cells. In
addition, the glucose uptake and lactate accumulations were escalated in PKD1
expressing cells. These results evidently affirmed the role of PKD1 in altering glucose
metabolism. Additionally, in vitro results demonstrated that the invasive and migratory
properties of PDAC cells were distinctly augmented in presence of induced PKD1 levels.
These tumorigenic abilities of PKD1+/+ or PKD1+/- cells were amplified after the
exposure with L-Lactate, a growth inducer while we observed converse effects during
2DG (negative deregulator) treatments.
Next, to comprehend the precise mechanism of PKD1 in dysregulating the
glucose metabolism, we determined the several downstream key players. Among the all,
proteins related to mTOR signaling were distinctly altered during the overexpression of
PKD1. From protein profiling studies, we observed induced expression of p-mTOR (ser2448), s6kinase, 4EBP1, and AKT in PKD1 overexpressing PDAC cells. Contrastingly,
the phosphorylated levels of mTOR and ps6kinase expressions were declined during
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silencing of PKD1 and mTOR inhibition. These results deduced the physiological role of
PKD1 in functioning of mTOR complex. In addition, lactate and glucose assays
reconfirmed these results as glucose consumption and lactate secretion was reduced when
raptor was silenced, but no difference was observed on silencing rictor in PKD1
expressing pancreatic cancer cells, annotating the functional relevance of mTORC1 in
mediating aberrant glucose metabolism. Also, we observed the silencing of PKD1
chemo-sensitizes PDAC cells towards gemcitabine treatments. The overall outcomes of
this study distinctly evidenced the role of PKD1 by causing the alterations in glucose
metabolic network through mTORC1 complex, that apparently led to worsening of the
disease. From these results we enacted PKD1 as prominent key player in causing aberrant
glucose metabolism in pancreatic cancer.
Previously, in chapter 2 and 3, we elucidated the oncogenic roles of MUC13 and
PKD1 respectively and their roles in dysregulated glucose metabolism in pancreatic
cancer. However, in chapter 4 we propose the therapeutic perspective which specifically
antagonize the functions of MUC13 and PKD1 proteins. The reason behind the selection
of phytochemicals along the wide array of chemical agents is since it can minimize the
toxicity issues and have potential to inhibit more than one molecular target in pancreatic
cancer cells. In Chapter 4, we identified a drug- steviol, which is a plant product and thus
has minimal to low toxicity. Steviol can be enacted as therapeutic agent in dual modes for
reinstating glucose metabolism. Firstly, it can play as a food supplement that mimics
glucose, that facilitates enhanced glucose uptake, and subsequently improves impaired
glucose metabolism. Secondly, due to its therapeutic roles with accumulated intracellular
levels exhibit potent anti-cancer effects. The anti-tumorigenic activity of steviol was
evaluated through proliferation and other functional studies. Steviol exhibited dose
dependent growth inhibitory effects on pancreatic cancer cells by restoring the
dysregulated glucose metabolism and it also inhibited both MUC13 and PKD1 proteins.
The molecular effects of steviol include the inhibition of translation-initiation complex
that stalled the growth of cells and promoted the cell arrest at G1 phase in pancreatic
cancer. From these events subsequently, cells were compelled to activate the apoptotic
cascade resulting in cell death. Altogether, we proposed an efficient method therapy that
effectively reconstructs the aberrant glucose metabolism and also targets MUC13 and
PKD1 proteins in pancreatic cancer cells (Figure 5-1). As steviol is a non-toxic natural
product, we believe that it can be used as an adjuvant in combination with known
therapeutic agents of pancreatic cancer. Altogether, we can hope to decrease the lethality
rates of pancreatic cancer patients by utilizing these effective strategies.
In the future, we can elucidate the role of these molecular determinants by using
the MUC13/PKD1 overexpressing or knockdown pancreatic cancer cells. Moreover, their
role in pancreatic carcinogenesis can be defined by genetic approach using Cre-Lox
mediated technology. Also, as we expect that steviol can be used as a preventive agent,
therefore, we can further investigate the chemo-preventive effects of Steviol against
pancreatic cancer in an appropriate spontaneous mouse model (p48 Cre//KRas), which
very closely represents pancreatic cancer progression in humans. This will enable us to
delineate the molecular mechanisms and the in vivo effects of steviol. Also, outcome of
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Figure 5-1. Schematic Diagram Representing the Overall Conclusion of the Study
MUC13 and PKD1 were identified as essential contributing molecules for promoting
dysregulated glucose metabolism in pancreatic cancer. Steviol, a natural plant product,
demonstrated anti-cancer effects for the first time in pancreatic cancer. It also suppressed
aberrant glucose metabolism and inhibited the expression of both MUC13 and PKD1
proteins, suggesting its strong therapeutic potential.
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this chemo-preventive study will set the stage for future phase I clinical trial against
pancreatic cancer in humans. In this proposed study, Steviol (about 1000 mg, orally) can
be given either to those patients who have high risk for developing pancreatic cancer or
early stage cancer patients (only having PanIN lesions). These studies will provide better
insights with respect to effectiveness of steviol in humans.
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